Diabetes, Obesity and Metabolism
Journal Impact IF - Analysis · Trend · Prediction · Ranking


New

Journal Impact IF

2019-2020

5.9

-3.8 %

Journal Impact IF Trend

Related Journals

Popular Journals

Diabetes, Obesity and Metabolism

The 2019-2020 Journal Impact IF of Diabetes, Obesity and Metabolism is 5.9, which is just updated in 2020.

Diabetes, Obesity and Metabolism Impact Factor
Highest IF
6.715
Highest Journal Impact IF

The highest Journal Impact IF of Diabetes, Obesity and Metabolism is 6.715.

Lowest IF
3.379
Lowest Journal Impact IF

The lowest Journal Impact IF of Diabetes, Obesity and Metabolism is 3.379.

Total Growth Rate
74.6%
IF Total Growth Rate

The total growth rate of Diabetes, Obesity and Metabolism IF is 74.6%.

Annual Growth Rate
8.3%
IF Annual Growth Rate

The annual growth rate of Diabetes, Obesity and Metabolism IF is 8.3%.

Journal Impact IF Ranking

Subcategory Quartile Rank Percentile
Endocrinology Q1 11/118

Endocrinology 91%

Internal Medicine Q1 10/128

Internal Medicine 92%

Endocrinology, Diabetes and Metabolism Q1 18/217

Endocrinology, Diabetes and Metabolism 91%

Journal Impact IF Ranking

· In the Endocrinology research field, the Quartile of Diabetes, Obesity and Metabolism is Q1. Diabetes, Obesity and Metabolism has been ranked #11 over 118 related journals in the Endocrinology research category. The ranking percentile of Diabetes, Obesity and Metabolism is around 91% in the field of Endocrinology.
· In the Internal Medicine research field, the Quartile of Diabetes, Obesity and Metabolism is Q1. Diabetes, Obesity and Metabolism has been ranked #10 over 128 related journals in the Internal Medicine research category. The ranking percentile of Diabetes, Obesity and Metabolism is around 92% in the field of Internal Medicine.
· In the Endocrinology, Diabetes and Metabolism research field, the Quartile of Diabetes, Obesity and Metabolism is Q1. Diabetes, Obesity and Metabolism has been ranked #18 over 217 related journals in the Endocrinology, Diabetes and Metabolism research category. The ranking percentile of Diabetes, Obesity and Metabolism is around 91% in the field of Endocrinology, Diabetes and Metabolism.

Diabetes, Obesity and Metabolism Impact Factor 2020-2021 Prediction

Diabetes, Obesity and Metabolism Impact Factor Predition System

Diabetes, Obesity and Metabolism Impact Factor Prediction System is now online. You can start share your valuable insights with the community.

Predict Check All Preditions
Total Publications
4692
Total Citations
151354

Annual Publication Volume

Annual Citation Record

International Collaboration Trend

Cited Documents Trend

Journal Impact IF History

Year Journal Impact IF
Year Journal Impact IF
2019-2020 5.9
2018-2019 6.133
2017-2018 5.98
2016-2017 6.715
2015-2016 6.198
2014-2015 6.36
2013-2014 5.456
2012-2013 5.181
2011-2012 3.379
Journal Impact IF History

· The 2019-2020 Journal Impact IF of Diabetes, Obesity and Metabolism is 5.9
· The 2018-2019 Journal Impact IF of Diabetes, Obesity and Metabolism is 6.133
· The 2017-2018 Journal Impact IF of Diabetes, Obesity and Metabolism is 5.98
· The 2016-2017 Journal Impact IF of Diabetes, Obesity and Metabolism is 6.715
· The 2015-2016 Journal Impact IF of Diabetes, Obesity and Metabolism is 6.198
· The 2014-2015 Journal Impact IF of Diabetes, Obesity and Metabolism is 6.36
· The 2013-2014 Journal Impact IF of Diabetes, Obesity and Metabolism is 5.456
· The 2012-2013 Journal Impact IF of Diabetes, Obesity and Metabolism is 5.181
· The 2011-2012 Journal Impact IF of Diabetes, Obesity and Metabolism is 3.379

Publications Cites Dataset

Year Publications Citations
Year Publications Citations
1998 0 2
1999 54 25
2000 57 77
2001 62 243
2002 68 424
2003 67 767
2004 59 1214
2005 102 1456
2006 90 1991
2007 162 3076
2008 176 4181
2009 187 5103
2010 161 5934
2011 166 7496
2012 180 9679
2013 179 11320
2014 175 13386
2015 174 13194
2016 190 13342
2017 252 13080
2018 401 12203
2019 810 14652
2020 873 17326
2021 47 1183
Publications Cites Dataset

· The Diabetes, Obesity and Metabolism has published 0 reports and received 2 citations in 1998.
· The Diabetes, Obesity and Metabolism has published 54 reports and received 25 citations in 1999.
· The Diabetes, Obesity and Metabolism has published 57 reports and received 77 citations in 2000.
· The Diabetes, Obesity and Metabolism has published 62 reports and received 243 citations in 2001.
· The Diabetes, Obesity and Metabolism has published 68 reports and received 424 citations in 2002.
· The Diabetes, Obesity and Metabolism has published 67 reports and received 767 citations in 2003.
· The Diabetes, Obesity and Metabolism has published 59 reports and received 1214 citations in 2004.
· The Diabetes, Obesity and Metabolism has published 102 reports and received 1456 citations in 2005.
· The Diabetes, Obesity and Metabolism has published 90 reports and received 1991 citations in 2006.
· The Diabetes, Obesity and Metabolism has published 162 reports and received 3076 citations in 2007.
· The Diabetes, Obesity and Metabolism has published 176 reports and received 4181 citations in 2008.
· The Diabetes, Obesity and Metabolism has published 187 reports and received 5103 citations in 2009.
· The Diabetes, Obesity and Metabolism has published 161 reports and received 5934 citations in 2010.
· The Diabetes, Obesity and Metabolism has published 166 reports and received 7496 citations in 2011.
· The Diabetes, Obesity and Metabolism has published 180 reports and received 9679 citations in 2012.
· The Diabetes, Obesity and Metabolism has published 179 reports and received 11320 citations in 2013.
· The Diabetes, Obesity and Metabolism has published 175 reports and received 13386 citations in 2014.
· The Diabetes, Obesity and Metabolism has published 174 reports and received 13194 citations in 2015.
· The Diabetes, Obesity and Metabolism has published 190 reports and received 13342 citations in 2016.
· The Diabetes, Obesity and Metabolism has published 252 reports and received 13080 citations in 2017.
· The Diabetes, Obesity and Metabolism has published 401 reports and received 12203 citations in 2018.
· The Diabetes, Obesity and Metabolism has published 810 reports and received 14652 citations in 2019.
· The Diabetes, Obesity and Metabolism has published 873 reports and received 17326 citations in 2020.
· The Diabetes, Obesity and Metabolism has published 47 reports and received 1183 citations in 2021.
· The total publications of Diabetes, Obesity and Metabolism is 4692.
· The total citations of Diabetes, Obesity and Metabolism is 151354.

What is Impact Factor?

The impact factor (IF) or journal impact factor (JIF) of an academic journal is a scientometric index calculated by Clarivate that reflects the yearly average number of citations of articles published in the last two years in a given journal. It is frequently used as a proxy for the relative importance of a journal within its field; journals with higher impact factor values are often deemed to be more important, or carry more intrinsic prestige in their respective fields, than those with lower values.

Diabetes, Obesity and Metabolism | Academic Accelerator - About the Impact Factor

Impact factor is commonly used to evaluate the relative importance of a journal within its field and to measure the frequency with which the “average article” in a journal has been cited in a particular time period. Journal which publishes more review articles will get highest IFs. Journals with higher IFs believed to be more important than those with lower ones. According to Eugene Garfield “impact simply reflects the ability of the journals and editors to attract the best paper available.” Journal which publishes more review articles will get maximum IFs. The Impact Factor of an academic journal is a scientometric Metric that reflects the yearly average number of citations that recent articles published in a given journal received. It is frequently used as a Metric for the relative importance of a journal within its field; journals with higher Impact Factor are often deemed to be more important than those with lower ones. The Diabetes, Obesity and Metabolism Impact Factor IF measures the average number of citations received in a particular year (2020) by papers published in the Diabetes, Obesity and Metabolism during the two preceding years (2018-2019). Note that 2020 Impact Factor are reported in 2021; they cannot be calculated until all of the 2020 publications have been processed by the indexing agency. New journals, which are indexed from their first published issue, will receive an impact factor after two years of indexing; in this case, the citations to the year prior to Volume 1, and the number of articles published in the year prior to Volume 1, are known zero values. Journals that are indexed starting with a volume other than the first volume will not get an impact factor until they have been indexed for three years. Occasionally, Journal Citation Reports assigns an impact factor to new journals with less than two years of indexing, based on partial citation data. The calculation always uses two complete and known years of item counts, but for new titles one of the known counts is zero. Annuals and other irregular publications sometimes publish no items in a particular year, affecting the count. The impact factor relates to a specific time period; it is possible to calculate it for any desired period. In addition to the 2-year Impact Factor, the 3-year Impact Factor, 4-year Impact Factor, 5-year Impact Factor, Real-Time Impact Factor can provide further insights and factors into the impact of Diabetes, Obesity and Metabolism.

History

The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information (ISI). Impact factors are calculated yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR). ISI was acquired by Thomson Scientific & Healthcare in 1992, and became known as Thomson ISI. In 2018, Thomson ISI was sold to Onex Corporation and Baring Private Equity Asia. They founded a new corporation, Clarivate, which is now the publisher of the JCR.

Use

The impact factor is used to compare different journals within a certain field. The Web of Science indexes more than 11,500 science and social science journals. Journal impact factors are often used to evaluate the merit of individual articles and individual researchers. This use of impact factors was summarised by Hoeffel:

Impact Factor is not a perfect tool to measure the quality of articles but there is nothing better and it has the advantage of already being in existence and is, therefore, a good technique for scientific evaluation. Experience has shown that in each specialty the best journals are those in which it is most difficult to have an article accepted, and these are the journals that have a high impact factor. Most of these journals existed long before the impact factor was devised. The use of impact factor as a measure of quality is widespread because it fits well with the opinion we have in each field of the best journals in our specialty....In conclusion, prestigious journals publish papers of high level. Therefore, their impact factor is high, and not the contrary.

Eugene Garfield

In brief, Impact factors may be used by:
  • Authors to decide where to submit an article for publication.
  • Libraries to make collection development decisions
  • Academic departments to assess academic productivity
  • Academic departments to make decisions on promotion and tenure.
As impact factors are a journal-level metric, rather than an article- or individual-level metric, this use is controversial. Garfield agrees with Hoeffel,but warns about the "misuse in evaluating individuals" because there is "a wide variation [of citations] from article to article within a single journal". Other things to consider about Impact Factors:
  • Many journals do not have an impact factor.
  • The impact factor cannot assess the quality of individual articles. Even if citations were evenly distributed among articles, the impact factor would only measure the interests of other researchers in an article, not its importance and usefulness.
  • Only research articles, technical notes and reviews are “citable” items. Editorials, letters, news items and meeting abstracts are “non-citable items”.
  • Only a small percentage of articles are highly cited and they are found in a small subset of journals. This small proportion accounts for a large percentage of citations.
  • Controversial papers, such as those based on fraudulent data, may be highly cited, distorting the impact factor of a journal.
  • Citation bias may exist. For example, English language resources may be favoured. Authors may cite their own work.
Moreover, informed and careful use of these impact data is essential, and should be based on a thorough understanding of the methodology used to generate impact factors. There are controversial aspects of using impact factors:
  • It is not clear whether the number of times a paper is cited measures its actual quality.
  • Some databases that calculate impact factors fail to incorporate publications including textbooks, handbooks and reference books.
  • Certain disciplines have low numbers of journals and usage. Therefore, one should only compare journals or researchers within the same discipline.
  • Review articles normally are cited more often and therefore can skew results.
  • Self-citing may also skew results.
  • Some resources used to calculate impact factors have inadequate international coverage.
  • Editorial policies can artificially inflate an impact factor.
Impact factors have often been used in advancement and tenure decision-making. Many recognize that this is a coarse tool for such important decisions, and that a multitude of factors should be taken into account in these deliberations. When considering the use of the impact factor (IF), keep these aspects in mind:
  • IF analysis is limited to citations from the journals indexed by the Web of Science/Web of Knowledge. Currently, the Web of Science indexes only 8621 journals across the full breadth of the sciences, and just 3121 in the social sciences.
  • A high IF/citation rate says nothing about the quality -- or even, validity -- of the references being cited. Notorious or even retracted articles often attract a lot of attention, hence a high number of citations. The notority related to the first publication on "cold fusion" is one such example.
  • Journals that publish more "review articles" are often found near the top of the rankings. While not known for publishing new, creative findings, these individual articles tend to be heavily cited.
  • The IF measures the average number of citations to articles in the journal -- given this, a small number of highly-cited articles will skew the figure.
  • It takes several years for new journals to be added to the list of titles indexed by the Web of Science/Web of Knowledge, so these newer titles will be under-represented.
  • It's alleged that journal editors have learned to "game" the system, encouraging authors to cite their works previously published in the same journal.
Comparing Journals Across Disciplines? Not a good idea! Using Impact Factors within a given discipline should only be done with great care, as described above. Using impact factor data to compare journals across disciplines is even more problematic. Here are some of the reasons:
  • Disciplines where older literature is still referenced, such as Chemistry and Mathematics, offer challenges to the methodolgy since older citations (older than two years) are not used to calculate the impact factor for a given journal. (Five-year impact factor analysis, which can be calculated using the Journal Citation Index database, helps smooth out this problem only to some degree.)
  • Different disciplines have different practices regarding tendency to cite larger numbers of references. Higher overall citation rates will bump upward impact factor measurements.
  • Where it's common for large numbers of authors to collaborate on a single paper, such as in Physics, the tendency of authors to cite themselves (and in this case, more authors) will result in increased citation rates.

Pros and Cons of the Impact Factor

Pros:

  • A vetted, established metric for measuring journal impact within a discipline.
  • Designed to eliminate bias based on journal size and frequency.
Cons:
  • Individual articles makes an uneven contribution to overall Impact Factor.
  • Impact Factor does not account for certain things, things like context (postive or negative citaion) and intentionality (self-citation).
  • The metric is proprietary to and bound by the contents of the Thomson Reuters database.
  • Citations, on which the Impact Factor is based, count for less than 1% of an article's overall use.

Criticism

Numerous critiques have been made regarding the use of impact factors. A 2007 study noted that the most fundamental flaw is that impact factors present the mean of data that are not normally distributed, and suggested that it would be more appropriate to present the median of these data. There is also a more general debate on the validity of the impact factor as a measure of journal importance and the effect of policies that editors may adopt to boost their impact factor (perhaps to the detriment of readers and writers). Other criticism focuses on the effect of the impact factor on behavior of scholars, editors and other stakeholders. Others have made more general criticisms, arguing that emphasis on impact factor results from negative influence of neoliberal policies on academia claiming that what is needed is not just replacement of the impact factor with more sophisticated metrics for science publications but also discussion on the social value of research assessment and the growing precariousness of scientific careers in higher education.
Experts stress that there are limitations in using impact factors to evaluate a scholar's work. There are many reasons cited for not relying on impact factor alone to evaluate the output of a particular individual. Among these are the following:

  • A single factor is not sufficient for evaluating an author's work.
  • Journal values are meaningless unless compared within the same discipline. Impact factors vary among disciplines.
  • The impact factor was originally devised to show the impact of a specific journal, not a specific scholar. The quality and impact of the author's work may extend beyond the impact of a particular journal.
According to Jim Testa, a researcher for ThomsonReuters Scientific, the most widespread misuse of the Impact Factor is to evaluate the work of an individual author (instead of a journal). "To say that because a researcher is publishing in a certain journal, he or she is more influential or deserves more credit is not necessarily true. There are many other variables to consider." (interview 6/26/2008 in Thomson Reuters blog entry)

Diabetes, Obesity and Metabolism
Journal Profile

About

Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter. Diabetes, Obesity and Metabolism is a monthly peer-reviewed medical journal established in 1999 covering research on diabetes, obesity, and metabolism. According to the Journal Citation Reports, the journal has a 2014 impact factor of 6.36.

Highly Cited Keywords

ISSN
1462-8902
ISSN

The ISSN of Diabetes, Obesity and Metabolism is 1462-8902 . An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

ISSN (Online)
1463-1326
ISSN (Online)

The ISSN (Online) of Diabetes, Obesity and Metabolism is 1463-1326 . An ISSN is an 8-digit code used to identify newspapers, journals, magazines and periodicals of all kinds and on all media–print and electronic.

Publisher
Wiley-Blackwell Publishing Ltd
Publisher

Diabetes, Obesity and Metabolism is published by Wiley-Blackwell Publishing Ltd .

Publication Frequency
Monthly
Publication Frequency

Diabetes, Obesity and Metabolism publishes reports Monthly .

Coverage
1999 - Present
Coverage

The Publication History of Diabetes, Obesity and Metabolism covers 1999 - Present .

Open Access
NO
Open Access

Diabetes, Obesity and Metabolism is Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles. Anyone who wants to use the articles in any way must obtain permission from the publishers.

Publication Fee
Publication Fee

There is no publication fee for submiting manuscript to Diabetes, Obesity and Metabolism. Diabetes, Obesity and Metabolism is Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles.

Language
English
Language

The language of Diabetes, Obesity and Metabolism is English .

Country/Region
United Kingdom
Country/Region

The publisher of Diabetes, Obesity and Metabolism is Wiley-Blackwell Publishing Ltd , which locates in United Kingdom .

Selected Articles

Full Title Authors
Full Title Authors
New clinical trial designs for establishing drug efficacy and safety in a precision medicine era Adie Viljoen · Christina Stentoft Hoxer · Pierre Johansen · Samuel Malkin · Barnaby Hunt · Stephen C. Bain · Stephen C. Bain
Adjusting insulin doses in patients with type 1 diabetes who use insulin pump and continuous glucose monitoring: Variations among countries and physicians Stefan Korsatko · Lene Jensen · Martina Brunner · Stefanie Sach-Friedl · Maja D. Tarp · Anders Gaarsdal Holst · Simon Heller · Thomas R. Pieber · Thomas R. Pieber
Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany Michael F. Crutchlow · John Palcza · Kate Mostoller · Chantal Mahon · April M. Barbour · Michael C. Marcos · Yang Xu · Elaine Watkins · Linda Morrow · Marcus Hompesch · Marcus Hompesch
Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1) Patrick B. Ryan · John B. Buse · Martijn J. Schuemie · Frank J. DeFalco · Zhong Yuan · Paul E. Stang · Jesse A. Berlin · Norman Rosenthal · Norman Rosenthal
Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes Brian M. Frier · Wolfgang Landgraf · Mei Zhang · Geremia B. Bolli · David Raymond Owens · David Raymond Owens
The bile acid‐sequestering resin sevelamer eliminates the acute GLP‐1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes Karolin Bettge · Melanie Kahle · Mirna S. Abd El Aziz · Juris J. Meier · Michael A. Nauck · Michael A. Nauck
Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study Nitin Gholap · Nitin Gholap · Felix A. Achana · Melanie J. Davies · Kausik K. Ray · Laura J. Gray · Kamlesh Khunti · Kamlesh Khunti
Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia Andreas Brønden · Anders Albér · Ulrich Rohde · Lærke S. Gasbjerg · Jens F. Rehfeld · Jens J. Holst · Tina Vilsbøll · Filip K. Knop · Filip K. Knop
Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes Takashi Kadowaki · Nobuya Inagaki · Kazuoki Kondo · Kenichi Nishimura · Genki Kaneko · Nobuko Maruyama · Nobuhiro Nakanishi · Maki Gouda · Hiroaki Iijima · Yumi Watanabe · Yumi Watanabe
Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study Colleen M. Craig · Li-Fen Liu · Thi Nguyen · Candice Price · Justus Bingham · Tracey McLaughlin · Tracey McLaughlin
Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes Yutaka Seino · Yasuo Terauchi · Takeshi Osonoi · Daisuke Yabe · Nobuyuki Abe · Tomoyuki Nishida · Jeppe Zacho · Shizuka Kaneko · Shizuka Kaneko
A First-in-Human Pharmacodynamic and Pharmacokinetic Study of a Fully-Human Anti-Glucagon Receptor Monoclonal Antibody in Normal Healthy Volunteers Frederik Persson · Thomas Nyström · Marit E. Jørgensen · Bendix Carstensen · Hanne L. Gulseth · Marcus Thuresson · Peter Fenici · David Nathanson · Jan W. Eriksson · Anna Norhammar · Johan Bodegard · Kåre I. Birkeland · Kåre I. Birkeland · Kåre I. Birkeland
Comment onComparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real‐world meta‐analysis of 4 observational databases (OBSERVE‐4D) Sruthi Adimadhyam · Todd A. Lee · Gregory S. Calip · Gregory S. Calip · Daphne E. Smith Marsh · Brian T. Layden · Glen T. Schumock · Glen T. Schumock
Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus Daniala L. Weir · Michal Abrahamowicz · Michal Abrahamowicz · Marie-Eve Beauchamp · Dean T. Eurich · Dean T. Eurich
Risk of amputations associated with SGLT2 inhibitors compared to DPP‐4 inhibitors: A propensity‐matched cohort study Lixin Guo · Li Chen · Baocheng Chang · Yang L · Yu Liu · Bo Feng · Bo Feng
Acute vs cumulative benefits of metformin use in patients with type 2 diabetes and heart failure Ralf Elvert · Andreas Herling · Martin Bossart · Tilo Weiss · Baohong Zhang · Pierre Wenski · Jörn Wandschneider · Sabrina Kleutsch · Uwe Butty · Aimo Kannt · Michael J. Wagner · Torsten Haack · Andreas Evers · Angela Dudda · Martin Lorenz · Stefanie Keil · Philip J. Larsen · Philip J. Larsen
A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral anti Eun Joo Roh · Eun Joo Roh · Kyoung Min Kim · Kyeong Seon Park · Yoon Kim · Eun Ju Chun · Sung H. Choi · Kyong Soo Park · Hak Chul Jang · Soo Lim · Soo Lim
Development of a cardiovascular diseases risk prediction model and tools for Chinese patients with type 2 diabetes mellitus: A population-based retrospective cohort study Patricia L. Mitchell · Renato Nachbar · Dominic Lachance · Philippe St-Pierre · Jocelyn Trottier · Olivier Barbier · André Marette · André Marette
Insights into optimal basal insulin titration in type 2 diabetes: results of a quantitative survey Daisuke Yabe · Takashi Eto M.D. · Masanari Shiramoto M.D. · Shin Irie · Kenta Murotani · Yusuke Seino · Hitoshi Kuwata · Takeshi Kurose · Dm Sci Susumu Seino Md · Bo Ahrén · Yutaka Seino · Yutaka Seino
Improving Type 2 Diabetes Mellitus glycaemic outcomes is possible without spending more on medication: Lessons from the UK National Diabetes Audit Eric Yuk Fai Wan · Daniel Tik-Pui Fong · Colman Siu Cheung Fung · Esther Yee Tak Yu · Wy Chin · Anca Ka Chun Chan · Cindy Lo Kuen Lam · Cindy Lo Kuen Lam
Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates Andrew R. Zullo · Michelle Hersey · Yoojin Lee · Sadia Sharmin · Elliott Bosco · Lori A. Daiello · Nishant R. Shah · Vincent Mor · W. John Boscardin · Christine M. Berard-Collins · David D. Dore · Michael A. Steinman · Michael A. Steinman
PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease Adrian Heald · Mark Livingston · Nagaraj Malipatil · Michal Becher · Joyce Craig · Mike Stedman · Anthony A. Fryer · Anthony A. Fryer
Therapeutic application of GPR119 ligands in metabolic disorders Christophe Schmitt · Agnès Portron · Shirin Jadidi · Neena Sarkar · Richard D. Dimarchi · Richard D. Dimarchi
Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non‐alcoholic fatty liver disease: A prospective randomized controlled pilot study Michael M. Page · Michael M. Page · Gerald F. Watts · Gerald F. Watts · Gerald F. Watts
The effect of exercise on sleep in adults with type 1 diabetes Jin Won Yang · Hyo Seon Kim · Yong-Won Choi · Young Mi Kim · Keon Wook Kang · Keon Wook Kang
Comparison of pancreatic volume and fat amount linked with glucose homeostasis between healthy Caucasians and Koreans Sean D. Sullivan · Timothy S. Bailey · Ronan Roussel · Ronan Roussel · Fang Liz Zhou · Zsolt Bosnyak · Ronald Preblick · Jukka Westerbacka · Rishab Gupta · Lawrence Blonde · Lawrence Blonde
Walnut consumption increases activation of the insula to highly desirable food cues: A randomized, double-blind, placebo-controlled, cross-over fMRI study Ravi Reddy · Joseph El Youssef · Kerri M. Winters-Stone · Deborah Branigan · Joseph Leitschuh · Jessica R. Castle · Peter G. Jacobs · Peter G. Jacobs
Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c Rakel Fuglsang Johansen · Esben Søndergaard · Helle Linnebjerg · Parag Garhyan · Eric Chen Quin Lam · Niels Porksen · Scott J. Jacober · Søren Nielsen · Søren Nielsen
Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK‐1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects Uta Neumann · Christoph Bührer · Oliver Blankenstein · Peter Kühnen · Klemens Raile · Klemens Raile
Attenuated Suppression of Lipolysis Explains Increases in Triglyceride Secretion and Concentration with Basal Insulin Peglispro (BIL) Relative to Insulin Glargine Treatment in Patients with Type 1 Diabetes Kamlesh Khunti · Marília de Brito Gomes · Stuart J. Pocock · Marina Vladimirovna Shestakova · Stéphane Pintat · Peter Fenici · Niklas Hammar · Niklas Hammar · Jesús Medina · Jesús Medina
Efficacy of a novel herbal formulation for weight loss demonstrated in a 16-week randomized, double-blind, placebo-controlled clinical trial with healthy overweight adults Véronique Gingras · Lisa Bonato · Virginie Messier · Amélie Roy-Fleming · Mohamed Raef Smaoui · Martin Ladouceur · Rémi Rabasa-Lhoret · Rémi Rabasa-Lhoret
Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial Laurentiu M. Pop · Andrea Mari · Tong Jin Zhao · Tong Jin Zhao · Lori Mitchell · Lori Mitchell · Shawn C. Burgess · Xilong Li · Beverley Adams-Huet · Ildiko Lingvay · Ildiko Lingvay
Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity Bo Ahrén · Stephen L. Atkin · Guillaume Charpentier · Mark L. Warren · John Wilding · Sune Birch · Anders Gaarsdal Holst · Lawrence A. Leiter · Lawrence A. Leiter
Roux-en-Y gastric bypass compared with equivalent diet restriction: Mechanistic insights into diabetes remission Ivana Rabbone · Nicola Minuto · Sonia Toni · Fortunato Lombardo · Dario Iafusco · Marco Marigliano · Riccardo Schiaffini · Giulio Maltoni · Anna Paola Frongia · Marco Scardapane · Antonio Nicolucci · Valentino Cherubini · Riccardo Bonfanti · Andrea Scaramuzza · Andrea Scaramuzza
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials Jean Ferrières · Dominik Lautsch · Anselm K. Gitt · Gaetano M. De Ferrari · Hermann Toplak · Moses Elisaf · Heinz Drexel · Martin Horack · Carl A. Baxter · Baishali Ambegaonkar · Philippe Brudi · Peter P. Toth · Peter P. Toth
Insulin pump breakdown and infusion set failure in Italian children with type 1 diabetes: A 1-year prospective observational study with suggestions to minimize clinical impact Yuya Tsurutani · Kazuki Nakai · Kosuke Inoue · Kosuke Azuma · Sei Mukai · Seitaro Maruyama · Takashi Iizuka · Yoko Matsuzawa · Jun Saito · Masao Omura · Tetsuo Nishikawa · Tetsuo Nishikawa
Body mass index impacts the choice of lipid-lowering treatment with no correlation to blood cholesterol - Findings from 52 916 patients in the Dyslipidemia International Study (DYSIS) Yasuo Terauchi · Matthew C. Riddle · Takahisa Hirose · Masayoshi Koyama · Xi Cheng · Yoshinori Takahashi · Geremia B. Bolli · Geremia B. Bolli
Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study Zihan Yan · Zeenat A. Shyr · Manuela Fortunato · Alecia Welscher · Mariana Alisio · Michael Martino · Brian N. Finck · Hannah Conway · Maria S. Remedi · Maria S. Remedi
Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12‐month comparison by concomitant sulphonylurea and/or glinide use Grit Andersen · Grégory Meiffren · Daniela Lamers · J. Hans DeVries · Aymeric Ranson · Cyril Seroussi · Bertrand Alluis · Martin Gaudier · Olivier Soula · Tim Heise · Tim Heise
High-fat-diet-induced remission of diabetes in a subset of KATP-GOF insulin-secretory-deficient mice Andreas Melmer · Andreas Melmer · Patrick Kempf · Lukas Lunger · Thomas R. Pieber · Julia K. Mader · Christoph Stettler · Herbert Tilg · Christoph F. Ebenbichler · Markus Laimer · Markus Laimer
Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes Kashinath Dixit · Dinesh V. Kamath · Krishnaraju V. Alluri · Barbara A. Davis · Barbara A. Davis
Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion and ketogenesis in type 1 diabetes mellitus: A randomized, placebo-controlled, double blind, cross-over pilot study Judith J. Stephenson · Amit D. Raval · David M. Kern · Jay P. Bae · Jay P. Bae
Non-adherence to basal insulin among patients with type 2 diabetes in a US managed care population: Results from a patient survey Danny H. Sugimoto · Terry Dex · William Stager · Vanita R. Aroda · Vanita R. Aroda
Primary sulfonylurea therapy in a newborn with transient neonatal diabetes due to a paternal uniparental disomy 6q24 (UPD6) Nadine Taleb · Ahmad Haidar · Virginie Messier · Véronique Gingras · Laurent Legault · Rémi Rabasa-Lhoret · Rémi Rabasa-Lhoret
Impact of macronutrient content of meals on postprandial glucose control in the context of closed-loop insulin delivery: A randomized cross-over study David J. Kazierad · Kristin Chidsey · Veena R. Somayaji · Arthur Bergman · Roberto A. Calle · Roberto A. Calle
Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements Jennifer M. Trujillo · Michelle Roberts · Terry Dex · Jason Chao · John R. White · James LaSalle · James LaSalle
Efficacy and safety of the glucagon receptor antagonist PF-06291874: A 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy Krit Jaikumkao · Anchalee Pongchaidecha · Nuttawud Chueakula · La-ongdao Thongnak · Keerati Wanchai · Keerati Wanchai · Varanuj Chatsudthipong · Nipon Chattipakorn · Anusorn Lungkaphin · Anusorn Lungkaphin
Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide alone Joakim Alfredsson · Joakim Alfredsson · Jennifer B. Green · Susanna R. Stevens · Shelby D. Reed · Paul W. Armstrong · M. Angelyn Bethel · Samuel S. Engel · Darren K. McGuire · Frans Van de Werf · Irene Hramiak · Harvey D. White · Eric D. Peterson · R R Holman · R R Holman
Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats Sandro Spiller · Matthias Blüher · Ralf Hoffmann · Ralf Hoffmann
Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS Martin Ridderstråle · Julio Rosenstock · Knut Robert Andersen · Hans J. Woerle · Afshin Salsali · Afshin Salsali
Plasma levels of free fatty acids correlate with type 2 diabetes mellitus Dirk Müller-Wieland · Monika Kellerer · Katarzyna Cypryk · Dasa Skripova · K. Rohwedder · Eva Johnsson · Ricardo Garcia-Sanchez · Raisa Kurlyandskaya · C. David Sjöström · Stephan Jacob · Jochen Seufert · Nalina Dronamraju · Katalin Csomós · Katalin Csomós
Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial Ki Heon Nam · Hae-Ryong Yun · Young Su Joo · Joohwan Kim · Sangmi Lee · Chang-Hyun Lee · Kyoung Sook Park · Jung Tak Park · Tae-Ik Chang · Ea Wha Kang · Tae-Hyun Yoo · Shin-Wook Kang · Seung Hyeok Han · Seung Hyeok Han
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes Lisa Logie · Zoe Lees · Zoe Lees · J. William Allwood · Gordon J. McDougall · Craig Beall · Graham Rena · Graham Rena
Changes in obese metabolic phenotypes over time and risk of incident chronic kidney disease Valma Harjutsalo · Merlin C. Thomas · Carol Forsblom · Per-Henrik Groop · Per-Henrik Groop
Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review Christopher K. Rayner · Karen L. Jones · Tongzhi Wu · Michael Horowitz · Michael Horowitz
Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea‐induced hypoglycaemia: A GoDARTS Study Daniël H. van Raalte · Daniël H. van Raalte · C. Bruce Verchere · C. Bruce Verchere
Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes Olivia M. Farr · Dario Tuccinardi · Jagriti Upadhyay · Sabrina M. Oussaada · Christos S. Mantzoros · Christos S. Mantzoros
Effect of Liraglutide on Ectopic Fat in Polycystic Ovary Syndrome: A Randomized Clinical Trial Tanja Dujic · Kaixin Zhou · Louise A. Donnelly · Graham P. Leese · Colin N. A. Palmer · Ewan R. Pearson · Ewan R. Pearson
On the etiology of type 1 diabetes: Physiological growth in children impacts disease progression Gian Paolo Fadini · Benedetta Maria Bonora · Sarangdhar Mayur · Mauro Rigato · Angelo Avogaro · Angelo Avogaro
Non-ST-elevation myocardial infarction outcomes in patients with type 2 diabetes with non-obstructive coronary artery stenosis: Effects of incretin treatment Michael Horowitz · Vanita R. Aroda · Jenny Han · Elise Hardy · Christopher K. Rayner · Christopher K. Rayner
Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double‐blind, active‐controlled, phase 3 trial Kathleen M. Dungan · Timothy E. Craven · Kyaw Soe · Jackson T. Wright · Jan N. Basile · William E. Haley · Nancy R. Kressin · Uzma Rani · Leonardo Tamariz · Jeff Whittle · Alan Wiggers · Kwame Osei · Kwame Osei
Influence of metabolic syndrome and race on the relationship between intensive blood pressure control and cardiovascular outcomes in the SPRINT cohort Niels B. Dalsgaard · Tina Vilsbøll · Filip K. Knop · Filip K. Knop
Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature Anna Solini · Chiara Rossi · Chiara M. Mazzanti · Agnese Proietti · Hermann Koepsell · Ele Ferrannini · Ele Ferrannini
Metformin and β-cell function in insulin-treated patients with type 2 diabetes: A randomized placebo-controlled 4.3-year trial Karen M. Hallow · Gabriel Helmlinger · Peter J. Greasley · John J.V. McMurray · David W. Boulton · David W. Boulton
Effects of glucagon-like peptide-1 (GLP-1) receptor agonists on cardiovascular risk factors: a narrative review of head-to-head comparisons Cristina B. Guzman · Hélène Dulude · Claude A. Piché · Marianne Rufiange · Aziz A. Sadoune · Emmanouil Rampakakis · Dolorès Carballo · Myriam Triest · Michelle Xiaotian Zhang · Shuyu Zhang · Maryam Tafreshi · Eric Sicard · Eric Sicard
Review of methods for measuring β‐cell function: Design considerations from the Restoring Insulin Secretion (RISE) Consortium Francesco Zaccardi · Nafeesa N. Dhalwani · Melanie J. Davies · Kamlesh Khunti · Kamlesh Khunti
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis David Russell-Jones · Frans Pouwer · Kamlesh Khunti · Kamlesh Khunti
Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial Herve Caspard · Serge Jabbour · Niklas Hammar · Niklas Hammar · Peter Fenici · John Sheehan · Mikhail Kosiborod · Mikhail Kosiborod
Identification of barriers to insulin therapy and approaches to overcoming them Oskar Skog · Olle Korsgren · Olle Korsgren · Olle Korsgren
Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014 Jennifer Leohr · Michael Heathman · Maria C. Kjellsson · Maria C. Kjellsson
A Semi-Physiologic Model of Postprandial Triglyceride Response in Lean, Obese and Very Obese Subjects Following a High Fat Meal Kamlesh Khunti · Mikhail Kosiborod · Mikhail Kosiborod
Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide Albert M. Kim · Veena R. Somayaji · Jennifer Q. Dong · Timothy P. Rolph · Yan Weng · Jeffrey R. Chabot · Kathryn E. Gropp · Saswata Talukdar · Roberto A. Calle · Roberto A. Calle
Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors Ankit Shah · Kiarra Levesque · Esmeralda Pierini · Betsy Rojas · Michael Ahlers · Sarah Stano · Marlena M. Holter · Roxanne Dutia · Scott Belsley · James McGinty · Blandine Laferrère · Blandine Laferrère · Blandine Laferrère
SGLT 2 inhibitors and cardiovascular outcome studies in Type 2 diabetes: From efficacy to effectiveness Manfredi Rizzo · Ali A. Rizvi · Giorgio Sesti · Giorgio Sesti
Effect of Sitagliptin on Glucose Control in Type 2 Diabetes Mellitus after Roux-en-Y Gastric Bypass Surgery Dorijn F. L. Hertroijs · Arianne Elissen · Martijn C. G. J. Brouwers · Nicolaas C. Schaper · Sebastian Köhler · Mirela Popa · Stylianos Asteriadis · Steven H. Hendriks · Henk J. G. Bilo · Dirk Ruwaard · Dirk Ruwaard
A risk score including body mass index, glycated haemoglobin and triglycerides predicts future glycaemic control in people with type 2 diabetes Susumu Seino · Kenji Sugawara · Norihide Yokoi · Harumi Takahashi · Harumi Takahashi
Anti-interleukin-1 therapy has mild hypoglycemic effect in type 2 diabetes Alena Welters · Carina Klüppel · Jessica Mrugala · Laura Wörmeyer · Thomas Meissner · Ertan Mayatepek · Christian Heiss · Daniel Eberhard · Eckhard Lammert · Eckhard Lammert
An arduous journey from human pluripotent stem cells to functional pancreatic β cells Guy A. Rutter · David J. Hodson · Pauline Chabosseau · Elizabeth Haythorne · Timothy J. Pullen · Isabelle Leclerc · Isabelle Leclerc
Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes Robert R. Henry · Julio Rosenstock · John F. McCarthy · Ginger Carls · Tom Alessi · John Yee · Michelle A. Baron · Michelle A. Baron
Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes Eric Wittbrodt · Amanda M. Kong · Laura Moore‐Schiltz · Paul Juneau · Paul Juneau
Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials Herbert Y. Gaisano · Herbert Y. Gaisano
All-cause and diabetes-related healthcare costs among US adults with type 2 diabetes initiating exenatide once weekly or insulin glargine Myfanwy Clare Geyer · Myfanwy Clare Geyer · Christopher K. Rayner · Christopher K. Rayner · Michael Horowitz · Michael Horowitz · Jennifer Couper · Jennifer Couper · Jennifer Couper
High-sensitivity C-reactive Protein, Low-Density Lipoprotein Cholesterol, and Cardiovascular Outcomes in Patients with Type 2 Diabetes in the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) Trial Tien Tang · Sally Abbott · Carel W. le Roux · Violet Wilson · Rishi Singhal · Srikanth Bellary · Srikanth Bellary · Srikanth Bellary · Abd A. Tahrani · Abd A. Tahrani · Abd A. Tahrani · Abd A. Tahrani
Do we know the true mechanism of action of the DPP‐4 inhibitors? Hertzel C. Gerstein · Helen M. Colhoun · Gilles R. Dagenais · Rafael Diaz · Mark Lakshmanan · Prem Pais · Jeffrey L. Probstfield · Matthew C. Riddle · Lars Rydén · Denis Xavier · Charles Atisso · Alvaro Avezum · Jan N. Basile · Namsik Chung · Ignacio Conget · William C. Cushman · Edward Franek · Nicolae Hancu · Markolf Hanefeld · Shaun Holt · Petr Jansky · Matyas Keltai · Fernando Lanas · Lawrence A. Leiter · Patricio López-Jaramillo · Ernesto Germán Cardona-Muñoz · Valdis Pirags · Nana Pogosova · Peter Raubenheimer · Jonathan E. Shaw · Wayne Huey-Herng Sheu · Theodora Temelkova-Kurktschiev · Theodora Temelkova-Kurktschiev
Islet neuropeptide Y receptors are functionally conserved and novel targets for the preservation of beta-cell mass Raffaele Marfella · Celestino Sardu · Paolo Calabrò · Mario Siniscalchi · Fabio Minicucci · Giuseppe Signoriello · Maria Luisa Balestrieri · Ciro Mauro · Maria Rosaria Rizzo · Giuseppe Paolisso · Michelangela Barbieri · Michelangela Barbieri
Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM) Carol H. Wysham · Julio Rosenstock · Marion L. Vetter · Fang Dong · Peter Öhman · Nayyar Iqbal · Nayyar Iqbal
Favourable changes in mortality in people with diabetes: US NHANES 1999–2010 Sergei Petrykiv · Gozewijn D. Laverman · Dick de Zeeuw · Hiddo J. Lambers Heerspink · Hiddo J. Lambers Heerspink
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis Signe Frøssing · Malin Nylander · Malin Nylander · Elizaveta Chabanova · Jan Frystyk · Jens J. Holst · Caroline Kistorp · Caroline Kistorp · Sven O. Skouby · Sven O. Skouby · Jens Faber · Jens Faber · Jens Faber
Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4) Simon Heller · Richard E. Pratley · Alan Sinclair · Andreas Festa · Jacek Kiljański · Cynthia S. Brusko · Ran Duan · Robert J. Heine · Robert J. Heine
Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A Post hoc Analysis of a Randomized Placebo-Controlled 4.3 year Trial Zhiying Wang · Jiahui Sun · Ruobing Han · Dongzhu Fan · Xinyi Dong · Zenghui Luan · Rongwu Xiang · Mingyi Zhao · Jingyu Yang · Jingyu Yang
The challenges of Achieving Postprandial Glucose Control using Closed-Loop Systems in Patients with Type 1 Diabetes Philip Home · Richard M. Bergenstal · Geremia B. Bolli · Monika Ziemen · Maria Rojeski · Melanie Espinasse · Matthew C. Riddle · Matthew C. Riddle
Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes Mattijs Out · Ida Miedema · Harriët Jager-Wittenaar · Cees P. van der Schans · Wim P. Krijnen · Philippe Lehert · Coen D. A. Stehouwer · Adriaan Kooy · Adriaan Kooy
Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic-euglycaemic clamp Véronique Gingras · Nadine Taleb · Amélie Roy-Fleming · Laurent Legault · Rémi Rabasa-Lhoret · Rémi Rabasa-Lhoret
Therapeutic inertia in patients treated with two or more antidiabetics in primary care: Factors predicting intensification of treatment Elizabeth M. Garry · John B. Buse · Jennifer L. Lund · Virginia Pate · Til Stürmer · Til Stürmer
Body fat distribution is more predictive of all‐cause mortality than overall adiposity Pierre Gourdy · Laurent Cazals · Claire Thalamas · Agnès Sommet · Fabienne Calvas · Monique Galitzky · Claire Vinel · Cédric Dray · H. Hanaire · Isabelle Castan-Laurell · Philippe Valet · Philippe Valet
Outcomes ofdiabetes-friendlyvsdiabetes-unfriendlyβ-blockers in older nursing home residents with diabetes after acute myocardial infarction Abraham H. Hulst · Jorinde A. W. Polderman · E. Ouweneel · A. J. Pijl · Markus W. Hollmann · J. H. DeVries · Benedikt Preckel · J. Hermanides · J. Hermanides
Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition Sung Woo Lee · Sung Woo Lee · Jee Young Son · Jeong Min Kim · Seung-Sik Hwang · Jin Suk Han Md · Nam Ju Heo · Nam Ju Heo
Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial Stefanie A. de Boer · Hiddo J. Lambers Heerspink · Luis Eduardo Juárez Orozco · Arie M. van Roon · Pieter Willem Kamphuisen · Andries J. Smit · Riemer H. J. A. Slart · Riemer H. J. A. Slart · Joop D. Lefrandt · Douwe J. Mulder · Douwe J. Mulder
Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study Lawrence A. Leiter · Bertrand Cariou · Dirk Müller-Wieland · Helen M. Colhoun · Stefano Del Prato · Francisco J. Tinahones · Kausik K. Ray · Maja Bujas-Bobanovic · Catherine Domenger · Jonas Mandel · Rita Samuel · Robert R. Henry · Robert R. Henry
Liraglutide and cardiovascular outcomes in adults with overweight or obesity: A post hoc analysis from SCALE randomized controlled trials Iskandar Idris · Iskandar Idris
Peri-operative continuation of metformin does not improve glycaemic control in patients with type 2 diabetes: A randomized controlled trial Zhong Yuan · Frank J. DeFalco · Patrick B. Ryan · Martijn J. Schuemie · Paul E. Stang · Jesse A. Berlin · Mehul Desai · Norm Rosenthal · Norm Rosenthal
Red wine polyphenols do not improve obesity‐associated insulin resistance: A randomized controlled trial Paolo Pozzilli · Paul Norwood · Esteban Jódar · Melanie J. Davies · Tibor Ivanyi · Honghua Jiang · D Bradley Woodward · Zvonko Milicevic · Zvonko Milicevic
Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 Diabetes (GIFT study) Katherine R. Tuttle · T. Dwight McKinney · Jaime A. Davidson · Greg Anglin · Kristine D. Harper · Fady T. Botros · Fady T. Botros
Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium‐glucose co‐transporter‐2 inhibitors in the USA: A retrospective cohort study Julie Hjerpsted · Anne Flint · Ashley Brooks · Mads Buhl Axelsen · Trine Kvist · John E. Blundell · John E. Blundell
Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals Matthew McCarthy · Matthew McCarthy · Charlotte L. Edwardson · Charlotte L. Edwardson · Melanie J. Davies · Melanie J. Davies · Joseph Henson · Joseph Henson · Alex V. Rowlands · Alex V. Rowlands · James A. King · Danielle H. Bodicoat · Danielle H. Bodicoat · Kamlesh Khunti · Kamlesh Khunti · Thomas Yates · Thomas Yates · Thomas Yates
Different intervention strategies for preventing type 2 diabetes mellitus in China: A systematic review and network meta-analysis of randomized controlled trials Serge Jabbour · Jochen Seufert · André Scheen · Clifford J. Bailey · Cathrina Karup · Anna Maria Langkilde · Anna Maria Langkilde
Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity Melanie J. Davies · Louis J. Aronne · Ian D. Caterson · Anne B. Thomsen · P. B. Jacobsen · Steven P. Marso · Steven P. Marso
A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents Nagendra R. Pokala · Beverley Adams-Huet · Xilong Li · Lindsay B. Harrison · Anna Vanderheiden · Ildiko Lingvay · Ildiko Lingvay
Severe hypoglycaemia among patients with type 2 diabetes requiring emergency hospital admission: The Hypoglycaemia In Portugal Observational Study–Emergency Room (HIPOS–ER) Michal Lips · Miloš Mráz · Jana Klouckova · Petr Kopecký · Milos Dobias · Jarmila Křížová · Jaroslav Lindner · Michaela Diamant · Martin Haluzik · Martin Haluzik
Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose-lowering interventions Pia Nørregaard · Maria A. Deryabina · Pernille Tofteng Shelton · Jacob Ulrik Fog · Jens R. Daugaard · Per‐Olof Eriksson · Lone F. Larsen · Lene Jessen · Lene Jessen
Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials Zara J Franklin · Anastasia Tsakmaki · Patricia Fonseca Pedro · Aileen King · Guo Cai Huang · Sakeena Amjad · Shanta J. Persaud · Gavin A. Bewick · Gavin A. Bewick
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study Christina C. Nexøe-Larsen · Pernille H. Sørensen · Helene Hausner · Mikkel Agersnap · Mille Baekdal · Andreas Brønden · Lea N. Gustafsson · David P. Sonne · David P. Sonne · Louise Vedtofte · Tina Vilsbøll · Tina Vilsbøll · Filip K. Knop · Filip K. Knop · Filip K. Knop
Glycaemic control in the diabetes and Lifestyle Cohort Twente: A cross-sectional assessment of lifestyle and pharmacological management on Hba1c target achievement Paola Fioretto · Stefano Del Prato · John B. Buse · Ronald Goldenberg · Francesco Giorgino · Daniel Reyner · Anna Maria Langkilde · C. David Sjöström · Peter Sartipy · Peter Sartipy · Peter Sartipy
Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment Predicts Greater Weight Loss Achieved by the Combination of Medical Weight Management And Bariatric Surgery In Patients With Type 2 Diabetes: A Longitudinal Analysis Leo Ka Yu Chan · Yi Wang · Enders K. Ng · Po Sing Leung · Po Sing Leung
Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial Revital Nimri · Eyal Dassau · Tomer Segall · Ido Muller · Natasa Bratina · Olga Kordonouri · Rachel Bello · Klemen Dovc · Ariel Tenenbaum · Ariel Tenenbaum · Avivit Brener · Marko Šimunović · Sophia Sakka · Michal Nevo Shenker · Caroline Gb Passone · I. Rutigliano · Davide Tinti · Clara Bonura · Silvana Caiulo · Anna Ruszala · Barbara Piccini · Dinesh Giri · Ronnie Stein · Ivana Rabbone · Patrizia Bruzzi · Jasna Šuput Omladič · Caroline Steele · Guglielmo Beccuti · Michal Yackobovitch-Gavan · Michal Yackobovitch-Gavan · Tadej Battelino · Tadej Battelino · Thomas Danne · Eran Atlas · Moshe Phillip · Moshe Phillip · Moshe Phillip
Legacy benefits of blood glucose, blood pressure and lipid control in individuals with diabetes and cardiovascular disease: Time to overcome multifactorial therapeutic inertia? Daphne N. Voormolen · J. Hans DeVries · Rieneke M. E. Sanson · Martijn P. Heringa · Harold W. de Valk · Marjolein Kok · Aren J. van Loon · Klaas Hoogenberg · Dick J. Bekedam · Teri C. B. Brouwer · Martina Porath · Ronald J. Erdtsieck · Bas NijBijvank · Huib Kip · Olivier W.H. van der Heijden · Lammy D. Elving · Brenda Hermsen · B.J. Potter van Loon · R.J. Rijnders · H. Jansen · Josje Langenveld · Bettina M.C. Akerboom · Rosalie M. Kiewiet · Christiana A. Naaktgeboren · Ben Willem J. Mol · Arie Franx · Inge M. Evers · Inge M. Evers
Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight Reinhard H.A. Becker · Reinhard H.A. Becker
Continuous glucose monitoring during diabetic pregnancy (GlucoMOMS): A multicentre randomized controlled trial Karin Rådholm · Karin Rådholm · John Chalmers · Toshiaki Ohkuma · Toshiaki Ohkuma · Sanne A.E. Peters · Neil Poulter · Pavel Hamet · Stephen B. Harrap · Mark Woodward · Mark Woodward · Mark Woodward
In response to: Heise T, Nørskov M, Nosek L, Kaplan K, Famulla S and Haahr H. L. (2017) Insulin degludec: Lower day‐to‐day and within‐day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes. Diabetes Obes Metab. 2017;19:1032–1039 Can Hou · Qian Xu · Sha Diao · Jonathan Hewitt · Jiayuan Li · Ben Carter · Ben Carter · Ben Carter · Ben Carter
Use of the waist-to-height ratio to predict cardiovascular risk in patients with diabetes: Results from the ADVANCE-ON study Emanuela Orsi · Anna Solini · Enzo Bonora · Cecilia Fondelli · Roberto Trevisan · Monica Vedovato · Franco Cavalot · Gabriella Gruden · Susanna Morano · Antonio Nicolucci · Giuseppe Penno · Giuseppe Pugliese · Giuseppe Pugliese
Mobile phone applications and self-management of diabetes: A systematic review with meta-analysis, meta-regression of 21 randomized trials and GRADE Hiddo J. Lambers Heerspink · Dennis L. Andress · George L. Bakris · Ricardo Correa-Rotter · Fan Fan Hou · Dalane W. Kitzman · Donald E. Kohan · Hirofumi Makino · John J.V. McMurray · Vlado Perkovic · Sheldon W. Tobe · Melissa Wigderson · Tingting Yi · Hans Henrik Parving · Hans Henrik Parving · Dick de Zeeuw · Dick de Zeeuw
Haemoglobin A1c variability is a strong, independent predictor of all-cause mortality in patients with type 2 diabetes Salvatore Carbone · Salvatore Carbone · Justin M. Canada · Hayley Billingsley · Dinesh Kadariya · Dave L. Dixon · Cory Trankle · Leo F. Buckley · Roshanak Markley · Chau Vo · Horacio Medina de Chazal · Sanah Christopher · Raffaella Buzzetti · Benjamin W. Van Tassell · Antonio Abbate · Antonio Abbate
Baseline characteristics and enrichment results from the SONAR trial Chantal Mathieu · Stefano Del Prato · Fady T. Botros · Vivian Thieu · Imre Pavo · Nan Jia · Axel Haupt · Chrisanthi A. Karanikas · Luis-Emilio Garcia-Perez · Luis-Emilio Garcia-Perez
Effects of empagliflozin on cardiorespiratory fitness and significant interaction of loop diuretics Samuel Dagogo-Jack · Jie Liu · Roy Eldor · Guillermo Amorin · Jeremy Johnson · Darcy A. Hille · Yuqin Liao · Susan Huyck · Gregory T. Golm · Steven G. Terra · James P. Mancuso · Samuel S. Engel · Brett Lauring · Brett Lauring
Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme Hertzel C. Gerstein · Ele Ferrannini · Matthew C. Riddle · Salim Yusuf · Origin Trial Investigators · Origin Trial Investigators
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study Husam Ghanim · Scott V. Monte · Joseph A. Caruana · Kelly Green · Sanaa Abuaysheh · Paresh Dandona · Paresh Dandona
Insulin resistance and cardiovascular outcomes in the ORIGIN trial Antonio E. Pontiroli · Valerio Ceriani · Valerio Ceriani
Decreases in neprilysin and vasoconstrictors and increases in vasodilators following bariatric surgery Anthony H. Barnett · Simon Arnoldini · Barnaby Hunt · Gowri Subramanian · Christina Stentoft Hoxer · Christina Stentoft Hoxer
Intranasal glucagon for hypoglycaemia in diabetic patients. An old dream is becoming reality Emilie S. Andersen · Asger Lund · Jonatan I. Bagger · Camilla Andreasen · Magnus F. Grøndahl · Carolyn F. Deacon · Bolette Hartmann · Jens J. Holst · Filip K. Knop · Tina Vilsbøll · Tina Vilsbøll
Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A Long-Term Cost-Effectiveness analysis Jessica P. S. Marshall · Jessica P. S. Marshall · Emma Estevez · Helene L. Kammoun · Emily J. King · Clinton R. Bruce · Brian G. Drew · Hongwei Qian · Peter Iliades · Paul Gregorevic · Mark A. Febbraio · Darren C. Henstridge · Darren C. Henstridge
Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? Yu Hong Chen · Chien-Ning Huang · Young Min Cho · Pengfei Li · Liqun Gu · Feng Wang · Jun Yang · Wei Qing Wang · Wei Qing Wang
Skeletal muscle-specific overexpression of heat shock protein 72 improves skeletal muscle insulin-stimulated glucose uptake but does not alter whole body metabolism Claire Fitzpatrick · Claire Fitzpatrick · Sudesna Chatterjee · Sudesna Chatterjee · Samuel Seidu · Danielle H. Bodicoat · Danielle H. Bodicoat · G Andre Ng · G Andre Ng · Melanie J. Davies · Melanie J. Davies · Melanie J. Davies · Kamlesh Khunti · Kamlesh Khunti · Kamlesh Khunti · Kamlesh Khunti
Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre, double-blind, randomized, parallel-arm, active comparator, phase III trial Xiao-Xue Zhu · Dalong Zhu · Xiaoying Li · Ya-Lin Li · Xiao-Wei Jin · Tianxin Hu · Yu Zhao · Yongguo Li · Guiyu Zhao · Shuang Ren · Yi Zhang · Yanhua Ding · Li Chen · Li Chen
Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: A systematic review and meta-analysis K.C.C. Petri · Steen H. Ingwersen · Anne Flint · Jeppe Zacho · Rune Viig Overgaard · Rune Viig Overgaard
Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection Maria Ida Maiorino · Paolo Chiodini · Giuseppe Bellastella · Lorenzo Scappaticcio · Miriam Longo · Katherine Esposito · Dario Giugliano · Dario Giugliano
Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes Johan Farngren · Margaretha Persson · Bo Ahrén · Bo Ahrén
Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials Ji H. Han · Hanho Shin · Jun Gi Rho · Jung-Eun Kim · Dong H. Son · Juhwan Yoon · Yong J. Lee · Jung-Hyuck Park · Byung Joo Song · Chang-Sik Choi · Seul Gi Yoon · Il Young Kim · Eun Kyung Lee · Je K. Seong · Ki Woo Kim · Wook Kim · Wook Kim
Effects on the glucagon response to hypoglycaemia during DPP‐4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo‐controlled study Yue Ma · Risheka Ratnasabapathy · Chioma Izzi-Engbeaya · Marie-Sophie Nguyen-Tu · Errol Richardson · Sufyan Hussain · Ivan De Backer · Christopher Holton · Mariana Norton · Gaelle Carrat · Blanche Schwappach · Guy A. Rutter · Waljit S. Dhillo · James Gardiner · James Gardiner
Peripheral cannabinoid 1 receptor blockade mitigates adipose tissue inflammation via NLRP3 inflammasome in mouse models of obesity Veronika Voronova · Kirill Zhudenkov · Robert C. Penland · David W. Boulton · Gabriel Helmlinger · Kirill Peskov · Kirill Peskov
Hypothalamic arcuate nucleus glucokinase regulates insulin secretion and glucose homeostasis Mikhail Kosiborod · Kåre I. Birkeland · Matthew A. Cavender · Alex Z. Fu · John Wilding · Kamlesh Khunti · Reinhard W. Holl · Anna Norhammar · Marit E. Jørgensen · Marit E. Jørgensen · Eric Wittbrodt · Marcus Thuresson · Johan Bodegard · Niklas Hammar · Niklas Hammar · Peter Fenici · Cvd-Real Investigators · Cvd-Real Investigators
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial Jeroen V. Koomen · Jasper Stevens · Nael M. Mostafa · Hans-Henrik Parving · Dick de Zeeuw · Hiddo J. Lambers Heerspink · Hiddo J. Lambers Heerspink
Direct medical costs of diabetes mellitus in the year of mortality and year preceding the year of mortality Kamlesh Khunti · Mikhail Kosiborod · Kausik K. Ray · Kausik K. Ray
Hypoglycaemia incidence and recovery during home use of hybrid closed-loop insulin delivery in adults with type 1 diabetes Juan P. Frías · Elise Hardy · Azazuddin Ahmed · Peter Öhman · Serge Jabbour · Hui Wang · Cristian Guja · Cristian Guja
Dapagliflozin for prednisone-induced hyperglycaemia in acute exacerbation of chronic obstructive pulmonary disease Jawad Bashir · Preethi Nalla · Rajesh Peter · Stephen C. Bain · Richard A. Chudleigh · Richard A. Chudleigh
Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach Paddy C. Dempsey · Robyn N. Larsen · Elisabeth Winkler · Neville Owen · Bronwyn A. Kingwell · David W. Dunstan · David W. Dunstan
Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine Lucía Cea-Soriano · Luis A. García-Rodríguez · Kimberly G. Brodovicz · Elvira Masso Gonzalez · Dorothee B. Bartels · Dorothee B. Bartels · Sonia Hernandez-Diaz · Sonia Hernandez-Diaz
Prolonged Uninterrupted Sitting Elevates Postprandial Hyperglycaemia Proportional to Degree of Insulin Resistance Anne Cathrine B. Thuesen · Allan Vaag · Allan Vaag
Safety of non-insulin glucose-lowering drugs in pregnant women with pre-gestational diabetes: A cohort study Håkan Malmström · Göran Walldius · Sofia Carlsson · Valdemar Grill · Ingmar Jungner · Soffia Gudbjörnsdottir · Mikhail Kosiborod · Niklas Hammar · Niklas Hammar · Niklas Hammar
Perspectives on diabetes mortality as the result of residual confounding and reverse causality by common disease Charles Khouri · Jean-Luc Cracowski · Matthieu Roustit · Matthieu Roustit
Elevations of metabolic risk factors 20 years or more before diagnosis of type 2 diabetes: Experience from the AMORIS study Robert R. Henry · Dirk Müller-Wieland · Pam R. Taub · Maja Bujas-Bobanovic · Michael J. Louie · Alexia Letierce · Henry N. Ginsberg · Henry N. Ginsberg
SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect? Jeremy Krebs · Jeremy Krebs · Mark Weatherall · Brian Corley · Brian Corley · Esko Wiltshire · Lindsay McTavish · Lindsay McTavish
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials Changting Xiao · Satya Dash · Priska Stahel · Gary F. Lewis · Gary F. Lewis
Optimizing the management of hypoglycaemia in individuals with type 2 diabetes: A randomized crossover comparison of a weight-based protocol compared with two fixed-dose glucose regimens V Schmid · Stephanie Kullmann · Wieland Gfrörer · Verena Hund · Manfred Hallschmid · Hans-Peter Lipp · Hans-Ulrich Häring · Hubert Preissl · Andreas Fritsche · Martin Heni · Martin Heni
Effects of intranasal insulin on endogenous glucose production in insulin-resistant men Maaike C. Gerards · Gerdien E. Venema · Kornelis W. Patberg · Martijn Kross · Bert Jan Potter van Loon · Ilse M. G. Hageman · Dominic Snijders · Dees P. M. Brandjes · Joost B. L. Hoekstra · Titia M. Vriesendorp · Victor E. A. Gerdes · Victor E. A. Gerdes
Safety of intranasal human insulin: a review K Laubner · Nina Riedel · Katharina Fink · Reinhard W. Holl · Reinhard Welp · Hans-Peter Kempe · Anne Lautenbach · Matthias Schlensak · Rainer Stengel · Thomas Eberl · Frank Dederichs · Henning Schwacha · Jochen Seufert · Jens Aberle · Jens Aberle
Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study Tao Huang · Tao Huang · Tiange Wang · Tiange Wang · Yoriko Heianza · Dianjianyi Sun · Kerry L. Ivey · Ronen Durst · Dan Schwarzfuchs · Meir J. Stampfer · Meir J. Stampfer · George A. Bray · Frank M. Sacks · Iris Shai · Lu Qi · Lu Qi · Lu Qi · Lu Qi
Brown adipose tissue lipid metabolism in morbid obesity: Effect of bariatric surgery-induced weight loss Carlos K. H. Wong · Fangfang Jiao · Eric H. M. Tang · Thaison Tong · Praveen Thokala · Cindy Lo Kuen Lam · Cindy Lo Kuen Lam
A case series of DKA occurring in patients receiving treatment with SGLT-2 inhibitors Hoe-Yune Jung · Bobae Kim · Hye Guk Ryu · Yosep Ji · Soyoung Park · Seung Hee Choi · Seung Hee Choi · Dohyun Lee · In-Kyu Lee · In-Kyu Lee · Munki Kim · You Jeong Lee · Woojin Song · Young-Hee Lee · Hyung Jin Choi · Chang-Kee Hyun · Wilhelm H. Holzapfel · Kyong-Tai Kim · Kyong-Tai Kim
HNF1A variant, energy-reduced diets and insulin resistance improvement during weight loss: The POUNDS Lost trial and DIRECT Shin Ichi Harashima · Nobuya Inagaki · Kazuoki Kondo · Nobuko Maruyama · Makiko Otsuka · Yutaka Kawaguchi · Yumi Watanabe · Yumi Watanabe
Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice David Polidori · Hiroaki Iijima · Maki Goda · Nobuko Maruyama · Nobuya Inagaki · Peter A. Crawford · Peter A. Crawford
Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study Hiddo J. Lambers Heerspink · Dennis L. Andress · George L. Bakris · Ricardo Correa-Rotter · Jyotirmoy Dey · Fan Fan Hou · Dalane W. Kitzman · Donald E. Kohan · Hirofumi Makino · John J.V. McMurray · Vlado Perkovic · Sheldon W. Tobe · Melissa Wigderson · Hans Henrik Parving · Hans Henrik Parving · Dick de Zeeuw · Dick de Zeeuw
Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin Tomohide Yamada · Nobuhiro Shojima · Hisashi Noma · Toshimasa Yamauchi · Takashi Kadowaki · Takashi Kadowaki
Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy Lennart Tonneijck · Marcel H.A. Muskiet · Mark M. Smits · Petter Bjornstad · Mark H. H. Kramer · Michaela Diamant · Ewout J. Hoorn · Jaap A. Joles · Daniël H. van Raalte · Daniël H. van Raalte
Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials Kevin M. Pantalone · Hiren Patel · Maria Yu · Laura Fernández Landó · Laura Fernández Landó
Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials Jaret Malloy · Dongliang Zhuang · Terri Kim · Phil Inskeep · Dennis Kim · Kristin Taylor · Kristin Taylor
Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration Wathik Alsalim · Margaretha Persson · Bo Ahrén · Bo Ahrén
Single and multiple dose evaluation of a novel MetAP2 inhibitor: Results of a randomized, double-blind, placebo-controlled clinical trial Prince Dadson · Jarna C. Hannukainen · Mueez U Din · Mueez U Din · Minna Lahesmaa · Minna Lahesmaa · Kari K. Kalliokoski · Jussi Pihlajamäki · Henry K. Karlsson · Riitta Parkkola · Paulina Salminen · Kirsi A. Virtanen · Kirsi A. Virtanen · Pirjo Nuutila · Pirjo Nuutila · Pirjo Nuutila
Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients Yue Ruan · Lia Bally · Hood Thabit · Hood Thabit · Lalantha Leelarathna · Sara Hartnell · Martin Tauschmann · Malgorzata E. Wilinska · Mark L. Evans · Mark L. Evans · Julia K. Mader · Harald Kojzar · Sibylle Dellweg · Carsten Benesch · Sabine Arnolds · Thomas R. Pieber · Roman Hovorka · Roman Hovorka
Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model Javier Morales · Merces Assumpcao-Morales · Merces Assumpcao-Morales
Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD-REAL study Grigory Sidorenkov · Job F. M. van Boven · Trynke Hoekstra · Giel Nijpels · Klaas Hoogenberg · Petra Denig · Petra Denig
The 2018 update of the American College of Physicians glycaemic management recommendations: An invitation to continued inertia? Dong-mei Liu · Ioanna Mosialou · Jian-min Liu · Jian-min Liu
Empagliflozin as add‐on to linagliptin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52‐week, randomized, placebo‐controlled trial Jeremy Krebs · Jeremy Krebs · Jacob Arahill · Pip Cresswell · Mark Weatherall · Amber Parry-Strong · Amber Parry-Strong
Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial Claudia Guida · Laura J. McCulloch · Mahdieh Godazgar · Sam D Stephen · Charlotte Baker · Davide Basco · Jiawen Dong · Duan Chen · Anne Clark · Reshma Ramracheya · Reshma Ramracheya
Hypoglycaemia in hospitalized patients with or without heart failure Dana Avrahami · Yue J. Wang · Agnes Klochendler · Yuval Dor · Benjamin Glaser · Klaus H. Kaestner · Klaus H. Kaestner
Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY Clifford J. Bailey · Clifford J. Bailey
European Medicines Agency: approval of new glucose-lowering medicines for type 2 diabetes Richard David Leslie · Paolo Pozzilli · Anne L. Peters · Raffaella Buzzetti · Sudha S. Shankar · Zvonko Milicevic · Imre Pavo · Jeremie Lebrec · Sherry Martin · Nanette C. Schloot · Nanette C. Schloot
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: a randomized, open-label clinical trial Ryo Suzuki · Jun-ichi Eiki · Takashi Moritoyo · Kenichi Furihata · Akira Wakana · Yukari Ohta · Shigeru Tokita · Takashi Kadowaki · Takashi Kadowaki
Response to the comment on:Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 trials Anne Christin Meyer-Gerspach · Huynh Giao Ly · Stefan Borgwardt · Patrick Dupont · Christoph Beglinger · Lukas Van Oudenhove · Bettina K. Wölnerhanssen · Bettina K. Wölnerhanssen
Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naïve Japanese patients with type 2 diabetes mellitus Ryo Kawasaki · Ryo Kawasaki · Ryo Kawasaki · Tsuneo Konta · Kohji Nishida · Kohji Nishida
Endogenous GLP-1 alters postprandial functional connectivity between homeostatic and reward-related brain regions involved in regulation of appetite in healthy lean males: A pilotstudy Juan P. Frias · Manuel Puig Domingo · Luigi Meneghini · Raffaele Napoli · Minzhi Liu · Erika Soltes Rak · Vanita R. Aroda · Vanita R. Aroda
Lipid-lowering medication is associated with decreased risk of diabetic retinopathy and the need for treatment in patients with type 2 diabetes: A real-world observational analysis of a health claims database Peter Arner · Agné Kulyté · Kenneth Batchelor · Jurga Laurencikiene · James Livingston · Mikael Rydén · Mikael Rydén
More patients reach glycaemic control with a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) than with basal insulin at 12 weeks of treatment: A post hoc time-to-control analysis of LixiLan-O and LixiLan-L Ryuzo Kawamori · Masakazu Haneda · Keiko Suzaki · Gang Cheng · Kosuke Shiki · Yuki Miyamoto · Fernando Solimando · Christopher Lee · Jisoo Lee · Jyothis T. George · Jyothis T. George
Mapping of biguanide transporters in human fat cells and their impact on lipolysis Tomohiko Kimura · Atsushi Obata · Masashi Shimoda · Seizo Okauchi · Yukiko Kanda-Kimura · Yuka Nogami · Saeko Moriuchi · Hidenori Hirukawa · Kenji Kohara · Shuhei Nakanishi · Tomoatsu Mune · Kohei Kaku · Hideaki Kaneto · Hideaki Kaneto
Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β-cells in db/db mice: The earlier and longer, the better Marianne Lachaux · Jonatan Barrera-Chimal · Lionel Nicol · Isabelle Remy-Jouet · Sylvanie Renet · Anais Dumesnil · Didier Wecker · Vincent Richard · Peter Kolkhof · Frederic Jaisser · Antoine Ouvrard-Pascaud · Paul Mulder · Paul Mulder
The effect of small doses of fructose and allulose on postprandial glucose metabolism in type 2 diabetes: A double-blind, randomized, controlled, acute feeding, equivalence trial Akira Shimada · Toshiaki Hanafusa · Atsutaka Yasui · Ganghyuck Lee · Yusuke Taneda · Akiko Sarashina · Kosuke Shiki · Jyothis T. George · Nima Soleymanlou · Jan Marquard · Jan Marquard
The effect of additional mealtime insulin bolus using an insulin-to-protein ratio compared to usual carbohydrate counting on postprandial glucose in those with type 1 diabetes who usually follow a carbohydrate-restricted diet: A randomized cross-over tria Olivia M. Farr · Christos S. Mantzoros · Christos S. Mantzoros
Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction David S. H. Bell · Edison Goncalves · Edison Goncalves
Obese individuals with type 2 diabetes demonstrate decreased activation of the salience-related insula and increased activation of the emotion/salience-related amygdala to visual food cues compared to non-obese individuals with diabetes: A preliminary stu Marianne K. Poulsen · Birgitte Nellemann · Bo Martin Bibby · Hans Stødkilde-Jørgensen · Steen B. Pedersen · Henning Grønbæk · Søren Nielsen · Søren Nielsen
Increase in glycated haemoglobin concentrations after unwarranted prescription changes Anna L. Emanuel · Nicolien C. de Clercq · Annefleur M. Koopen · Erik van Poelgeest · Mireille J. Serlie · Daniël H. van Raalte · Mark H. H. Kramer · Max Nieuwdorp · Etto C. Eringa · Erik H. Serné · Erik H. Serné
No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease Kohei Kaku · Shingo Kuroda · Kazuyuki Ishida · Yuusuke Umeda · Yuusuke Umeda
Iloprost infusion prevents the insulin-induced reduction in skeletal muscle microvascular blood volume but does not enhance peripheral glucose uptake in type 2 diabetic patients Jingyi Qian · Jingyi Qian · Chiara Dalla Man · Christopher J. Morris · Christopher J. Morris · Claudio Cobelli · Frank A. J. L. Scheer · Frank A. J. L. Scheer · Frank A. J. L. Scheer
Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: Results from a randomized, Phase IV study Yves Reznik · Aklilu Habteab · Javier Castaneda · John J. Shin · Michael Joubert · Michael Joubert
Differential effects of the circadian system and circadian misalignment on insulin sensitivity and insulin secretion in humans J. Hans DeVries · Cyrus V. Desouza · Srikanth Bellary · Jeffrey Unger · Oluf K. H. Hansen · Jeppe Zacho · Vincent Woo · Vincent Woo
Contribution of basal and postprandial hyperglycaemia in type 2 diabetes patients treated by an intensified insulin regimen: Impact of pump therapy in the OPT2mise trial Katrien Benhalima · Elisabeth R. Mathiesen · Päivi M. Paldánius · Chantal Mathieu · Chantal Mathieu
Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme Kyung-Ah Han · Suk Chon · Choon Hee Chung · Soo Lim · Kwan-Woo Lee · S. H. Baik · Chang Hee Jung · Dong-Sun Kim · Kyong Soo Park · Kun-Ho Yoon · In-Kyu Lee · Bong Soo Cha · Taishi Sakatani · Sumi Park · Moon-Kyu Lee · Moon-Kyu Lee
The need for appropriate registration of pregnancy outcomes under newer oral glucose-lowering therapies Annis C. Jalving · Christina M. Gant · S. Heleen Binnenmars · Sabita S. Soedamah-Muthu · Sabita S. Soedamah-Muthu · Stephan J. L. Bakker · Gerjan Navis · Gozewijn D. Laverman · Gozewijn D. Laverman
Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials Jennifer Merrill · Kathleen M. Dungan · Kathleen M. Dungan
Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis Om P. Ganda · Jorge Plutzky · Santosh K. Sanganalmath · Maja Bujas-Bobanovic · Andrew Koren · Jonas Mandel · Alexia Letierce · Lawrence A. Leiter · Lawrence A. Leiter
HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups Gijs H. Goossens · Max A. A. Vogel · Roel G. Vink · Edwin C. M. Mariman · Marleen A. van Baak · Ellen E. Blaak · Ellen E. Blaak
Resveratrol effect on patients with non-alcoholic fatty liver disease: A matter of dose and treatment length Thomas C. Blevins · Abhijit Barve · Bin Sun · Michael Ankersen · Michael Ankersen
Bone: Another potential target to treat, prevent and predict diabetes Andrew Collier · Paul J. Connelly · Mario Hair · Lyall Cameron · Sujoy Ghosh · Norman Waugh · Norman Waugh
Adipose tissue oxygenation is associated with insulin sensitivity independently of adiposity in obese men and women Mark Warren · Louis Chaykin · David Trachtenbarg · Gurudutt Nayak · Nelun Wijayasinghe · Bertrand Cariou · Bertrand Cariou
Mortality risk remains higher in individuals with type 1 diabetes: A population-based cohort study (the Ayrshire diabetes follow-up cohort [ADOC]) Ronald Goldenberg · Peter Assimakopoulos · Jeremy Gilbert · Irving S. Gottesman · Jean-Francois Yale · Jean-Francois Yale
Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials J.A. Overbeek · Edith M. Heintjes · Eline L. Huisman · Christian Klyver Tikkanen · Arnout W. van Diermen · Fernie J. A. Penning-van Beest · R.M.C. Herings · R.M.C. Herings
A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes Christopher Ll. Morgan · Silvio E. Inzucchi · Jorge Puelles · Sara Jenkins-Jones · Craig John Currie · Craig John Currie
Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes Motoshi Ouchi · Kenzo Oba · Hideki Suganami · Akihiro Yoshida · Tomoe Fujita · Tatsuya Suzuki · Masahiro Yasutake · Kohei Kaku · Kohei Kaku
Impact of treatment with pioglitazone on stroke outcomes: A real-world database analysis Chi-Jung Huang · Wei-Ting Wang · Shih-Hsien Sung · Shih-Hsien Sung · Chen-Huan Chen · Chen-Huan Chen · Gregory Y.H. Lip · Gregory Y.H. Lip · Hao-Min Cheng · Chern-En Chiang · Chern-En Chiang · Chern-En Chiang
This is in reply to the Letter by Kahathuduwa et al. titledUnaccounted for regression to the mean renders conclusion of article titled Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin unsubstantiated Mattijs Out · Mattijs Out · Wiebe Top · Philippe Lehert · Casper A. Schalkwijk · Coen D. A. Stehouwer · Adriaan Kooy · Adriaan Kooy · Adriaan Kooy
Blood glucose reduction by diabetic drugs with minimal hypoglycaemia risk for cardiovascular outcomes: Evidence from meta‐regression analysis of randomized controlled trials Dianjianyi Sun · Yoriko Heianza · Xiang Li · Xiaoyun Shang · Steven R. Smith · George A. Bray · Frank M. Sacks · Frank M. Sacks · Lu Qi · Lu Qi · Lu Qi · Lu Qi
Long-term treatment with metformin in type 2 diabetes and vitamin D levels: A post hoc analysis of a randomised placebo-controlled trial Federica Fogacci · Maciej Banach · Arrigo F.G. Cicero · Arrigo F.G. Cicero
Genetic, epigenetic, and transcriptional variations at NFATC2IP locus with weight loss in response to diet interventions: The POUNDS Lost Trial Chee W. Chia · Michelle Shardell · Kristofer S. Gravenstein · Olga D. Carlson · Eleanor M. Simonsick · Luigi Ferrucci · Josephine M. Egan · Josephine M. Egan
Regular low‐calorie sweetener consumption is associated with increased secretion of glucose‐dependent insulinotropic polypeptide Chanaka N. Kahathuduwa · Chanaka N. Kahathuduwa · Diana M. Thomas · Cynthia Siu · David B. Allison · David B. Allison
The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting Jarvis C. Noronha · Jarvis C. Noronha · Catherine R. Braunstein · Catherine R. Braunstein · Andrea J. Glenn · Andrea J. Glenn · Tauseef A. Khan · Tauseef A. Khan · Effie Viguiliouk · Effie Viguiliouk · Rebecca Noseworthy · Rebecca Noseworthy · Sonia Blanco Mejia · Sonia Blanco Mejia · Cyril W.C. Kendall · Cyril W.C. Kendall · Cyril W.C. Kendall · Thomas M. S. Wolever · Lawrence A. Leiter · John L. Sievenpiper · John L. Sievenpiper
Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study Helen J Curtis · J Dennis · Beverley M. Shields · Alex J. Walker · Seb Bacon · Andrew T. Hattersley · Angus G. Jones · Ben Goldacre · Ben Goldacre
Unaccounted for regression to the mean renders conclusion of article titledUric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozinunsubstantiated Nirmala Pandeya · Nirmala Pandeya · Rachel Huxley · Hsin-Fang Chung · Annette Dobson · Diana Kuh · Rebecca Hardy · Janet E Cade · Darren C. Greenwood · Graham G. Giles · Graham G. Giles · Fiona Bruinsma · Panayotes Demakakos · Mette Kildevæld Simonsen · Hans-Olov Adami · Hans-Olov Adami · Elisabete Weiderpass · Gita D. Mishra · Gita D. Mishra
Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017 Peter Breining · Jonas Jensen · Elias I. Sundelin · Lars Christian Gormsen · Steen Jakobsen · Morten Busk · Lars Rolighed · Peter Bross · Paula Fernandez-Guerra · Lasse K. Markussen · Lasse K. Markussen · Nanna E. Rasmussen · Jacob B. Hansen · Steen B. Pedersen · Bjørn Richelsen · Niels Jessen · Niels Jessen · Niels Jessen
Female reproductive history and risk of type 2 diabetes: a prospective analysis of 126,721 women Josephine B. Hebsgaard · Charles Pyke · Emre Yildirim · Lotte Bjerre Knudsen · Steffen Heegaard · Peter Helding Kvist · Peter Helding Kvist
Metformin targets brown adipose tissue in vivo and reduces oxygen consumption in vitro François Curtin · Corinne Bernard · Sandrine Levet · Hervé Perron · Hervé Porchet · Julie Medina · Sam Malpass · David Lloyd · Richard Simpson · Richard Simpson
Glucagon-like peptide-1 receptor expression in the human eye Israel Hodish · Israel Hodish
A new therapeutic approach for type 1 diabetes: Rationale for GNbAC1, an anti-HERV-W-Env monoclonal antibody Sergio Rodriguez-Cuenca · Stefania Carobbio · Stefania Carobbio · Gwendolyn Barceló-Coblijn · Xavier Prieur · Joana Relat · Ramon Amat · Mark Campbell · Ana Rita Dias · Myriam Bahri · Myriam Bahri · Sarah L. Gray · Antonio Vidal-Puig · Antonio Vidal-Puig
Insulin therapy, weight gain and prognosis Tim Heise · Sascha Heckermann · J. Hans DeVries · J. Hans DeVries
P465L-PPARγ mutation confers partial resistance to the hypolipidaemic action of fibrates David S. H. Bell · Edison Goncalves · Edison Goncalves
Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing? Russell Drummond · Russell Drummond · Samuel Malkin · Michelle Du Preez · Xin Ying Lee · Barnaby Hunt · Barnaby Hunt
Should we still be utilizing warfarin in the type 2 diabetic patient Panagiotis Andreadis · Thomas Karagiannis · Konstantinos Malandris · Ioannis Avgerinos · Aris Liakos · Apostolos Manolopoulos · Eleni Bekiari · David R. Matthews · David R. Matthews · Apostolos Tsapas · Apostolos Tsapas · Apostolos Tsapas
Targeting Postprandial Glycaemia in Children with Diabetes: Opportunities and Challenges Kang Chen · Deying Kang · Miao Yu · Ruya Zhang · Ye Zhang · Guojuan Chen · Yiming Mu · Yiming Mu
Treatment Satisfaction with ITCA 650, a Novel Drug-device Delivering Continuous Exenatide versus Twice-Daily Injections of Exenatide in Type 2 Diabetics on Metformin You Cheol Hwang · David A. Morrow · Christopher P. Cannon · Yuyin Liu · Richard M. Bergenstal · Simon Heller · Cyrus R. Mehta · William C. Cushman · George L. Bakris · Faiez Zannad · William B. White · William B. White
Direct head-to-head comparison of glycemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: a meta-analysis of long-term randomized controlled trials Russell Brown · James Paul · James Paul
The effects of dietary supplementation with inulin and inulin-propionate ester on hepatic steatosis in adults with non-alcoholic fatty liver disease Justin M. Gregory · Margaret Lautz · Lindsey M. Moore · Phillip E. Williams · Praveen Reddy · Alan D. Cherrington · Alan D. Cherrington
Risk of heart failure in a population with type 2 diabetes versus a population without diabetes with and without coronary heart disease Gabby Elbaz-Greener · Olga Bloch · Ilya Kumets · Alex Blatt · Micha J. Rapoport · Micha J. Rapoport
Enterically delivered insulin tregopil exhibits rapid absorption characteristics and a pharmacodynamic effect similar to human insulin in conscious dogs Niina Matikainen · Sanni Söderlund · Elias Bjornson · Kirsi H. Pietiläinen · Antti Hakkarainen · Nina Lundbom · Marja-Riitta Taskinen · Jan Borén · Jan Borén
Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial Emily D. Parker · Eric Wittbrodt · Jeffrey T. McPheeters · Juan P. Frías · Juan P. Frías
Endogenous glucagon-like peptide-1 system response is impaired during ST-elevation myocardial infarction in type 2 diabetes patients Ji Cheol Bae · Kyung Wan Min · Yong Hyun Kim · Kyoung-Ah Kim · Eun-Gyoung Hong · Cheol-Young Park · Song Han · Bong Soo Cha · Bong Soo Cha
Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study Clifford J. Bailey · Nikolaus Marx · Nikolaus Marx
Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin P. Christensen · Thomas Meinert Larsen · Margriet S. Westerterp-Plantenga · Ian Macdonald · J. Alfredo Martínez · J. Alfredo Martínez · J. Alfredo Martínez · Svetoslav Handjiev · Sally D. Poppitt · Sylvia Hansen · Christian Ritz · Arne Astrup · Laura Pastor-Sanz · Finn Sandø-Pedersen · Kirsi H. Pietiläinen · Jouko Sundvall · Mathijs Drummen · Moira A. Taylor · Santiago Navas-Carretero · Santiago Navas-Carretero · Teodora Handjieva-Darlenska · Shannon Brodie · Marta Silvestre · Maija Huttunen-Lenz · Jennie Brand-Miller · Mikael Fogelholm · Anne Raben · Anne Raben
Efficacy and safety of fixed-dose combination therapy with gemigliptin (50 mg) and rosuvastatin compared with monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, phase 3 trial Alpana Shukla · Morgan Dickison · Morgan Dickison · Natasha Coughlin · Natasha Coughlin · Ampadi Karan · Elizabeth Mauer · Wanda Truong · Anthony Casper · Ana B. Emiliano · Rekha B. Kumar · Katherine H. Saunders · Leon I. Igel · Louis J. Aronne · Louis J. Aronne
Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials Eleni Rebelos · Heidi Immonen · Marco Bucci · Jarna C. Hannukainen · Lauri Nummenmaa · Miikka-Juhani Honka · Minna Soinio · Paulina Salminen · Ele Ferrannini · Pirjo Nuutila · Pirjo Nuutila · Pirjo Nuutila
Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW) Ioannis Avgerinos · Thomas Karagiannis · Konstantinos Malandris · Aris Liakos · Maria Mainou · Eleni Bekiari · David R. Matthews · David R. Matthews · Apostolos Tsapas · Apostolos Tsapas · Apostolos Tsapas
The impact of food order on postprandial glycaemic excursions in prediabetes Joachim Tillner · Maximilian G. Posch · Frank Wagner · Lenore Teichert · Youssef Hijazi · Christine Einig · Stefanie Keil · Torsten Haack · Michael J. Wagner · Martin Bossart · Philip J. Larsen · Philip J. Larsen
Brain glucose uptake is associated with endogenous glucose production in obese patients before and after bariatric surgery and predicts metabolic outcome at follow-up JinXiao Lian · JinXiao Lian · Sarah M. McGhee · Ching So · June Chau · Carlos K. H. Wong · William Wong · Cindy Lo Kuen Lam · Cindy Lo Kuen Lam
Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis Henny-Kristine Korsmo-Haugen · Kjetil Gundro Brurberg · Jim Mann · Anne-Marie Aas · Anne-Marie Aas
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials Adi Drori · Anna Permyakova · Rivka Hadar · Shiran Udi · Alina Nemirovski · Joseph Tam · Joseph Tam
Long-term cost-effectiveness of a Patient Empowerment Programme for type 2 diabetes mellitus in primary care Iskandar Idris · Iskandar Idris
Carbohydrate quantity in the dietary management of type 2 diabetes: A systematic review and meta-analysis Thomas C. Blevins · Abhijit Barve · Bin Sun · Yaron Raiter · Patrick Aubonnet · Rafael Muniz · Sandeep Athalye · Michael Ankersen · Michael Ankersen
Cannabinoid-1 receptor regulates mitochondrial dynamics and function in renal proximal tubular cells Suzanne V. Arnold · Leo Seman · Fengming Tang · Poghni Peri-Okonny · Keith C. Ferdinand · Sanjeev N. Mehta · Abhinav Goyal · Laurence Sperling · Mikhail Kosiborod · Mikhail Kosiborod
News and Views for September 2018: Highlights from the American Diabetes Association Scientific meeting, June 2018 Gian Paolo Fadini · Anna Solini · Maria Laura Manca · Giuseppe Penno · Adriano Gatti · Roberto Anichini · Stefano Del Prato · Angelo Avogaro · Angelo Avogaro
Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study Suzanne V. Arnold · Jonathan Yap · Carolyn S.P. Lam · Fengming Tang · Wan T. Tay · Tiew H.K. Teng · Darren K. McGuire · James L. Januzzi · Gregg C. Fonarow · Frederick A. Masoudi · Mikhail Kosiborod · Mikhail Kosiborod
Real-world opportunity of empagliflozin to improve blood pressure control in African American patients with type 2 diabetes: A National Cardiovascular Data Registryresearch-to-practiceproject from the diabetes collaborative registry Karim Gariani · Dan Lebowitz · Elodie Von Dach · Benjamin Kressmann · Benjamin A. Lipsky · Benjamin A. Lipsky · Ilker Uckay · Ilker Uckay
Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study David S. H. Bell · Edison Goncalves · Edison Goncalves
Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison Weiqing Wang · Luis Nevárez · Ekaterina Filippova · Ki Ho Song · Bei Tao · Liqun Gu · Feng Wang · Pengfei Li · Jun Yang · Jun Yang
Remission in diabetic foot infections: Duration of antibiotic therapy and other possible associated factors Andrea Granados · Achamyeleh Gebremariam · Samuel S. Gidding · James G. Terry · J. Jeffrey Carr · Lyn M. Steffen · David R. Jacobs · Joyce M. Lee · Joyce M. Lee · Joyce M. Lee
Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies Edward Yu · Miguel Ruiz-Canela · Miguel Ruiz-Canela · Cristina Razquin · Marta Guasch-Ferré · Marta Guasch-Ferré · Marta Guasch-Ferré · Estefanía Toledo · Estefanía Toledo · Dong D. Wang · Christopher Papandreou · Courtney Dennis · Clary B. Clish · Liming Liang · Mònica Bulló · Dolores Corella · Dolores Corella · Montserrat Fitó · Montserrat Fitó · Mario Gutiérrez-Bedmar · José Lapetra · Ramón Estruch · Ramón Estruch · Emilio Ros · Emilio Ros · Montserrat Cofán · Montserrat Cofán · Fernando Arós · Dora Romaguera · Lluis Serra-Majem · Lluis Serra-Majem · José V. Sorlí · José V. Sorlí · Jordi Salas-Salvadó · Jordi Salas-Salvadó · Frank B. Hu · Frank B. Hu · Miguel Ángel Martínez-González · Miguel Ángel Martínez-González
Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial Geremia B. Bolli · Carol H. Wysham · Miles Fisher · Soazig Chevalier · Anna M.G. Cali · Bruno Leroy · Matthew C. Riddle · Matthew C. Riddle
Association of abdominal muscle composition with prediabetes and diabetes: The CARDIA study Sumie Okahata · Kentaro Sakamoto · Takako Mitsumatsu · Yuko Kondo · Shoji Tanaka · Teruo Shiba · Teruo Shiba
Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component? Kohei Kaku · Masakazu Haneda · Yuko Tanaka · Ganghyuck Lee · Kosuke Shiki · Yuki Miyamoto · Fernando Solimando · Jisoo Lee · Christopher Lee · Jyothis T. George · Jyothis T. George
Persistent elevations in circulating INS DNA among subjects with longstanding type 1 diabetes Hua-Fen Chen · Hua-Fen Chen · Ching-An Ho · Chung-Yi Li · Chung-Yi Li · Chung-Yi Li
A review of dipeptidyl peptidase‐4 inhibitors. Hot topics from randomized controlled trials Chan-Hee Jung · Eun-Jung Rhee · Won Young Lee · Kyung Wan Min · Vyankatesh K. Shivane · Aravind R. Sosale · Hak Chul Jang · Choon Hee Chung · Il Seong Nam-Goong · Il Seong Nam-Goong
Elevated GlycA in severe obesity is normalized by bariatric surgery Francesco Prattichizzo · Valeria De Nigris · Stefano Micheloni · Lucia La Sala · Antonio Ceriello · Antonio Ceriello
Residual confounding in the study by van Dalem et al Sudesna Chatterjee · Melanie J. Davies · Kamlesh Khunti · Kamlesh Khunti
A 52-week extension study of switching from gemigliptin vs sitagliptin to gemigliptin only as add-on therapy for patients with type 2 diabetes who are inadequately controlled with metformin alone Michael A. Nauck · Juris J. Meier · Juris J. Meier
Higher mortality rate in patients with heart failure who are taking commonly prescribed antidiabetic medications and achieve recommended levels of glycaemic control Susan Tran · Ravi Retnakaran · Ravi Retnakaran · Ravi Retnakaran · Bernard Zinman · Bernard Zinman · Bernard Zinman · Caroline K. Kramer · Caroline K. Kramer · Caroline K. Kramer
What have we learnt fromreal worlddata, observational studies and meta‐analyses Martin Haluzik · Greg Fulcher · Thomas R. Pieber · Lars Bardtrum · Deniz Tutkunkardas · Helena W. Rodbard · Helena W. Rodbard
Incretin hormones: Their role in health and disease Shelby D. Reed · Yifan Li · Jose Leal · Larry Radican · Amanda I. Adler · Joakim Alfredsson · John B. Buse · Jennifer B. Green · Keith D. Kaufman · Axel Riefflin · F. Van de Werf · Eric D. Peterson · Alastair Gray · R R Holman · R R Holman
Efficacy of glucagon‐like peptide‐1 receptor agonists compared to dipeptidyl peptidase‐4 inhibitors for the management of type 2 diabetes: A meta‐analysis of randomized clinical trials Jiun-Ling Wang · Yaa-Hui Dong · Wen-Chien Ko · Chia-Hsuin Chang · Li-Chiu Wu · Lee-Ming Chuang · Pau-Chung Chen · Pau-Chung Chen
The co‐formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta‐analysis of phase III studies in patients with type 2 diabetes Nienke M.A. Idzerda · Frederik Persson · Michelle J. Pena · Barry M. Brenner · Patrick Brunel · Nish Chaturvedi · John J.V. McMurray · Hans-Henrik Parving · Dick de Zeeuw · Hiddo J. Lambers Heerspink · Hiddo J. Lambers Heerspink
Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Young-Gun Kim · Ja Young Jeon · Seung Jin Han · Dae Jung Kim · Kwan-Woo Lee · Hae Jin Kim · Hae Jin Kim
Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: A population-based cohort study Takashi Kadowaki · Nobuaki Sarai · Takeshi Hirakawa · Kentaro Taki · Kosuke Iwasaki · Hisashi Urushihara · Hisashi Urushihara
NT-proBNP predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk Chioma Izzi-Engbeaya · Alexander Comninos · Alexander Comninos · Sophie Clarke · Anne Jomard · Lisa Yang · S. C. P. Jones · Ali Abbara · Shakunthala Narayanaswamy · Pei Chia Eng · Deborah Papadopoulou · Julia K. Prague · Paul Bech · Ian F. Godsland · Paul Bassett · Caroline Sands · Stephane Camuzeaux · María Gómez-Romero · Jake T. M. Pearce · Matthew R. Lewis · Elaine Holmes · Jeremy K. Nicholson · Tricia Tan · Risheka Ratnasabapathy · Ming Hu · Gaelle Carrat · Lorenzo Piemonti · Marco Bugliani · Piero Marchetti · Paul Johnson · Paul Johnson · Stephen J. Hughes · Stephen J. Hughes · A. M. James Shapiro · Guy A. Rutter · Waljit S. Dhillo · Waljit S. Dhillo
Sodium-glucose co-transporter-2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population-based cohort study Sarah K. Lyons · Claire T. Boyle · Daniel J. DeSalvo · Michael R. Rickels · Lauren K. Wood Heickman · Kellee M. Miller · Nicole C. Foster · Mark A. Clements · Mark A. Clements
Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics and severity of renal impairment: A Japanese database analysis F. Javier Escalada Md · S. Halimi · Peter A. Senior · Peter A. Senior · Mireille Bonnemaire · Anna M.G. Cali · Lydie Melas-Melt · Janaka Karalliedde · Robert Ritzel · Robert Ritzel
The Effects of Kisspeptin on β-cell Function, Serum Metabolites and Appetite in Humans Adham Mottalib · Adham Mottalib · Shaheen Tomah · Samar Hafida · Taha Elseaidy · Megan Kasetty · Megan Kasetty · Sahar Ashrafzadeh · Osama Hamdy · Osama Hamdy
Dyslipidaemia and statin use in individuals aged 10 to <40 years in the T1D Exchange clinic registry Eric Renard · Eric Renard · Nadia Tubiana-Rufi · Elisabeth Bonnemaison-Gilbert · R. Coutant · Fabienne Dalla-Vale · Anne Farret · Amélie Poidvin · Natacha Bouhours-Nouet · Charlotte Abettan · Caroline Storey-London · Aurélie Donzeau · Jerome Place · Marc D. Breton · Marc D. Breton
Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment David G. Bruce · Wendy A. Davis · Timothy M. E. Davis · Timothy M. E. Davis
Intensive multidisciplinary weight management in patients with type 1 diabetes and obesity: A one-year retrospective matched cohort study Sebastian Diebold · Julia Moellmann · Florian Kahles · Elias Haj-Yehia · Elisa A. Liehn · Alexander Nickel · Corinna Lebherz · Christoph Maack · Nikolaus Marx · Michael Lehrke · Michael Lehrke
Closed-loop driven by control-to-range algorithm outperforms threshold-low-glucose-suspend insulin delivery on glucose control albeit not on nocturnal hypoglycaemia in prepubertal patients with type 1 diabetes in a supervised hotel setting Rune Viig Overgaard · Søren Ø. Lindberg · Desirée Thielke · Desirée Thielke
Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II Emanuel Raschi · Elisabetta Poluzzi · Gian Paolo Fadini · Giulio Marchesini · Fabrizio De Ponti · Fabrizio De Ponti
Myocardial infarction is sufficient to increase GLP-1 secretion, leading to improved left ventricular contractility and mitochondrial respiratory capacity Huilin Tang · Keming Yang · Yiqing Song · Jiali Han · Jiali Han
Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach Francesca Piccinini · David Polidori · Barbara A. Gower · Jose R. Fernandez · Richard N. Bergman · Richard N. Bergman
Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough? Ghadeer K. Dawwas · Steven M. Smith · Haesuk Park · Haesuk Park
Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes Domenico Tricò · Domenico Tricò · Andrea Natali · Andrea Mari · Ele Ferrannini · Nicola Santoro · Sonia Caprio · Sonia Caprio
Dissection of hepatic versus extra-hepatic insulin clearance: Ethnic differences in childhood Arun Manmadhan · Bing-Xue Lin · Judy Zhong · Manish Parikh · Edward A. Fisher · Sean P. Heffron · Sean P. Heffron
Cardiovascular Outcomes of Sodium Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes Anna Neyman · Jennifer B. Nelson · Sarah A. Tersey · Raghavendra G. Mirmira · Carmella Evans-Molina · Emily K. Sims · Emily K. Sims
Triglyceride-rich very low-density lipoproteins (VLDL) are independently associated with insulin secretion in a multiethnic cohort of adolescents Edward S. Chambers · Claire S. Byrne · Annette Rugyendo · Douglas J. Morrison · Tom Preston · M. Catriona Tedford · Jimmy D. Bell · E. Louise Thomas · Arne N. Akbar · Natalie E. Riddell · Rohini Sharma · Mark Thursz · Pinelopi Manousou · Gary Frost · Gary Frost
Changes in Arginine are Inversely Associated with Type 2 Diabetes: A Case‐Cohort Study in the PREDIMED Trial Ming Liu · Ming Liu · Michael A. Weiss · Michael A. Weiss · Anoop Arunagiri · Jing Yong · Nischay Rege · Jinhong Sun · Jinhong Sun · Leena Haataja · Randal J. Kaufman · Peter Arvan · Peter Arvan
A post-hoc pooled analysis to evaluate the risk of hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in individuals with type 2 diabetes on a basal-only insulin regimen Desiree Abdurrachim · Xing Qi Teo · Chern Chiuh Woo · Wei Xin Chan · Janise Lalic · Carolyn S.P. Lam · Carolyn S.P. Lam · Philip Teck Hock Lee · Philip Teck Hock Lee
Mechanistic insights from sequential combination therapy with a sodium glucose co‐transporter‐2 inhibitor and a dipeptidyl peptidase‐4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin Kåre I. Birkeland · Valdemar Grill · Cecilie Wium · Matthew J. McQueen · Patricio López-Jaramillo · Shun Fu Lee · Hertzel C. Gerstein · Hertzel C. Gerstein
Biosynthesis, structure, and folding of the insulin precursor protein Lydia Farack · Adi Egozi · Shalev Itzkovitz · Shalev Itzkovitz
Effects of intensifying triple oral antidiabetic drug therapy by initiating insulin versus enhancing oral antidiabetic drug therapy on clinical outcomes in patients with type 2 diabetes: a nationwide population-based, propensity score-matched cohort study Aris Liakos · Vaia Lambadiari · Alexandra Bargiota · Konstantinos Kitsios · Iakovos Avramidis · Kalliopi Kotsa · Spyridon Gerou · Panagiota Boura · Nikolaos Tentolouris · George Dimitriadis · Apostolos Tsapas · Apostolos Tsapas
Mineralocorticoid antagonism enhances brown adipose tissue function in humans: A randomized placebo-controlled cross-over study Michael A. Nauck · John B. Buse · Johannes F.E. Mann · Stuart J. Pocock · Heidrun Bosch-Traberg · Helle Frimer-Larsen · Qing Ye · Alastair Gray · Alastair Gray
Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin-treated T2DM patients: Results from the Qatar Study Ahmed Al-Qaissi · Maria Papageorgiou · Harshal. Deshmukh · Leigh A. Madden · Alan S. Rigby · Eric S. Kilpatrick · Stephen L. Atkin · Thozhukat Sathyapalan · Thozhukat Sathyapalan
Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial Myfanwy Clare Geyer · Myfanwy Clare Geyer · Thomas Sullivan · Andrew Tai · Andrew Tai · Judith M. Morton · Judith M. Morton · Suzanne Edwards · A. James Martin · A. James Martin · Shiree J. Perano · Lucia Gagliardi · Lucia Gagliardi · Christopher K. Rayner · Christopher K. Rayner · Michael Horowitz · Michael Horowitz · Jennifer Couper · Jennifer Couper · Jennifer Couper
Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial John B. Buse · Mitsuhisa Komatsu · Ludger Rose · Bo Liang · Kristine Buchholtz · Hiroshi Horio · Takashi Kadowaki · Takashi Kadowaki
The effects of acute insulin-induced hypoglycaemia on endothelial microparticles in adults with and without type 2 diabetes Stephen C. Bain · Rosario Arechavaleta · Paweł Bogdański · Abdurrahman Comlekci · Agostino Consoli · Chaicharn Deerochanawong · Kathleen M. Dungan · Maria C. Faingold · Michael E. Farkouh · Denise R. Franco · Jeppe Gram · Cristian Guja · Pankaj Joshi · Rachid Malek · Juan F. Merino-Torres · Michael A. Nauck · Sue D. Pedersen · Wayne Huey-Herng Sheu · Robert J. Silver · Cees J. Tack · Nikhil Tandon · Ole K. Jeppesen · Mette Strange · Mette Thomsen · Mansoor Husain · Mansoor Husain · Mansoor Husain
Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: A randomized crossover trial Saverio Stranges · Margaret P. Rayman · Kristian Hillert Winther · Eliseo Guallar · Søren Cold · Roberto Pastor-Barriuso · Roberto Pastor-Barriuso
Fast‐acting insulin aspart versus insulin aspart in the setting of insulin degludec‐treated type 1 diabetes: efficacy and safety from a randomized double‐blind trial João P. Magalhães · Pedro B. Júdice · Pedro B. Júdice · Rogério Tavares Ribeiro · Rita Andrade · João Filipe Raposo · Hélder Dores · Manuel Bicho · Luís B. Sardinha · Luís B. Sardinha
Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial Marta García-Fiñana · David Hughes · Christopher P. Cheyne · Deborah Broadbent · Deborah Broadbent · Amu Wang · Arnošt Komárek · I M Stratton · Mehrdad Mobayen-Rahni · Mehrdad Mobayen-Rahni · Ayesh Alshukri · Jiten Vora · Simon P. Harding · Simon P. Harding · Simon P. Harding
Effect of selenium supplementation on changes in glycated haemoglobin (HbA1c): Results from a multiple-dose, randomized controlled trial Ian Pearce · Rafael Simó · Monica Lövestam-Adrian · David T. Wong · Marc Evans · Marc Evans
Effectiveness of high intensity interval training combined with resistance training vs. continuous moderate intensity training combined with resistance training in patients with type 2 diabetes - 1 year randomized controlled trial Skander Mulder · Habib Hamidi · Matthias Kretzler · Wenjun Ju · Wenjun Ju
Personalized risk-based screening for diabetic retinopathy: a multivariate approach vs. the use of stratification rules Ulrike Hövelmann · Minna Braendholt Olsen · Ulrik Mouritzen · Daniela Lamers · Birgit Kronshage · Tim Heise · Tim Heise
Association between diabetic eye disease and other complications of diabetes: implications for care. A systematic review Akinobu Nakamura · Kazuno Omori · Takahiro Takase · Aika Miya · Naoki Manda · Yoshio Kurihara · Shin Aoki · Tatsuya Atsumi · Hideaki Miyoshi · Hideaki Miyoshi
An integrative systems biology approach for precision medicine in diabetic kidney disease Patrick Lee · Bruce R. Yacyshyn · Mary Beth Yacyshyn · Mary Beth Yacyshyn
Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus Peter G. M. Mol · Aliza Thompson · Hiddo J. Lambers Heerspink · Hubert G. M. Leufkens · Hubert G. M. Leufkens
Effect of switching from pioglitazone to the SGLT2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type-2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial Petter Bjornstad · Sunita K. Singh · Janet K. Snell-Bergeon · Julie A. Lovshin · Yuliya Lytvyn · Leif E. Lovblom · Marian Rewers · Genevieve Boulet · Vesta Lai · Josephine Tse · Leslie Cham · Andrej Orszag · Alanna Weisman · Hillary A. Keenan · Michael H. Brent · Narinder Paul · Vera Bril · Bruce A. Perkins · Bruce A. Perkins · David Z.I. Cherney · David Z.I. Cherney
Gut microbiota and obesity: An opportunity to alter obesity through Fecal Microbiota Transplant (FMT) Berit Christoffersen · Ellen M. Straarup · Kirsten Lykkegaard · Johannes Josef Fels · Kristian Sass-Ørum · Xujia Zhang · Kirsten Raun · Birgitte Andersen · Birgitte Andersen
Precision medicine in diabetes and diabetic kidney disease : Regulatory considerations Liyuan Han · Liyuan Han · Donghui Duan · Donghui Duan · Donghui Duan · Shuang Zhang · Weiqin Li · Leishen Wang · Huikun Liu · Junhong Leng · Nan Li · Xiaoyun Shang · Gang Hu · Lu Qi · Lu Qi
The Relationships between Markers of Tubular Injury and Intrarenal Hemodynamic Function in Adults with and without Type 1 Diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes Julio Rosenstock · Yehuda Handelsman · Josep Vidal · F. Javier Ampudia Blasco · Francesco Giorgino · Minzhi Liu · Riccardo Perfetti · Juris J. Meier · Juris J. Meier
FGF21 decreases food intake and body weight in obese Göttingen minipigs Hiddo J. Lambers Heerspink · Dick de Zeeuw · Dick de Zeeuw
Effects of the interaction between glycated haemoglobin genetic risk score and postpartum weight reduction on glycaemic changes: A gene-weight interaction analysis Ahmed Al-Qaissi · Maria Papageorgiou · Zeeshan Javed · Tim Heise · Alan S. Rigby · Andrew Garrett · David Hepburn · Eric S. Kilpatrick · Stephen L. Atkin · Thozhukat Sathyapalan · Thozhukat Sathyapalan
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes Felix Aberer · Katharina M. Lichtenegger · Edin Smajic · Klaus Donsa · Oliver Malle · Judith Samonigg · Bernhard Höll · Peter Beck · Thomas R. Pieber · Thomas R. Pieber · Johannes Plank · Julia K. Mader · Julia K. Mader
Treating diabetic complications; from large randomized clinical trials to precision medicine Hiddo J. Lambers Heerspink · James List · Vlado Perkovic · Vlado Perkovic
Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus J. Hans DeVries · Timothy S. Bailey · Anuj Bhargava · Gregg Gerety · Janusz Gumprecht · Simon Heller · Wendy Gwirtzman Lane · Carol H. Wysham · Bernard Zinman · Britta A. Bak · Elise Hachmann-Nielsen · Athena Philis-Tsimikas · Athena Philis-Tsimikas
GlucoTab guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalised patients with type 2 diabetes Yong Hyun Kim · Eun Seok Kang · Hak Chul Jang · Dong Jun Kim · Taekeun Oh · Eun Sook Kim · N.H. Kim · Kyung Mook Choi · Sung-Rae Kim · JiYoung You · Se-Jin Kim · Moon-Kyu Lee · Moon-Kyu Lee
Short chain fatty acids stimulate insulin secretion and reduce apoptosis in mouse and human islets in vitro: Role of free fatty acid receptor 2 Muhammad A. Abdul-Ghani · Muhammad A. Abdul-Ghani · Osama Migahid · Ayman Megahed · Rajvir Singh · Mohammad Fawaz · Ralph A. DeFronzo · Amin Jayyousi · Amin Jayyousi
Regulation of islet glucagon secretion: Beyond calcium Moe Thuzar · Moe Thuzar · Weikiat Phillip Law · Weikiat Phillip Law · Goce Dimeski · Goce Dimeski · Michael Stowasser · Michael Stowasser · Ken K. Y. Ho · Ken K. Y. Ho · Ken K. Y. Ho
Time zones of pancreatic islet metabolism Shihchen Kuo · Chun-Ting Yang · Jin-Shang Wu · Huang-Tz Ou · Huang-Tz Ou
When one becomes many-Alternative splicing in β-cell function and failure Dan Siskind · Margaret Hahn · Margaret Hahn · Christoph U. Correll · Christoph U. Correll · Anders Fink-Jensen · Anders Fink-Jensen · Anthony W. Russell · Anthony W. Russell · Nikolaj Bak · Brian V. Broberg · Julie Rask Larsen · Julie Rask Larsen · Pelle L. Ishøy · Tina Vilsbøll · Filip K. Knop · Steve Kisely · Bjørn H. Ebdrup · Bjørn H. Ebdrup
Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13C magnetic resonance spectroscopy study Yi-Chun Chen · Austin J. Taylor · C. Bruce Verchere · C. Bruce Verchere
The association of basal insulin treatment versus standard care with outcomes in anti-GAD positive and negative subjects: A post-hoc analysis of the ORIGIN trial Swantje Brede · Sebastian Fehr · Chiara Dalla-Man · Claudio Cobelli · Hendrik Lehnert · Manfred Hallschmid · Johanna Klement · Johanna Klement
Single molecule approaches for studying gene regulation in metabolic tissues Kamlesh Khunti · Samuel Seidu · Melanie J. Davies · Melanie J. Davies
Islet prohormone processing in health and disease Fan Yan Wei · Kazuhito Tomizawa · Kazuhito Tomizawa
Intranasal oxytocin fails to acutely improve glucose metabolism in obese men Yael Riahi · Tal Israeli · Erol Cerasi · Gil Leibowitz · Gil Leibowitz
Should sodium glucose co-transporter 2 inhibitors be considered as first line oral therapy for people with type 2 diabetes? Jochen Seufert · Andreas Fritsche · Stefan Pscherer · Helmut Anderten · Anja Borck · Katrin Pegelow · Peter Bramlage · Martin Pfohl · Martin Pfohl
tRNA modifications and islet function Frederik Persson · Thomas Nyström · Marit E. Jørgensen · Bendix Carstensen · Hanne L. Gulseth · Marcus Thuresson · Peter Fenici · David Nathanson · Jan W. Eriksson · Anna Norhammar · Johan Bodegard · Kåre I. Birkeland · Kåre I. Birkeland
Effects of proinsulin misfolding on β-cell dynamics, differentiation and function in diabetes Avivit Cahn · Cheli Melzer-Cohen · Rena Pollack · Gabriel Chodick · Varda Shalev · Varda Shalev
Titration and optimization trial for the initiation of insulin glargine 100 U/mL in inadequately controlled type-2 diabetes patients on oral antidiabetic drugs Tiziana Napolitano · Serena Silvano · Andhira Vieira · Shruti Balaji · Anna Garrido-Utrilla · Marika Friano · Josipa Atlija · Patrick Collombat · Patrick Collombat
Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis Othmar Moser · Max L. Eckstein · Alexander Mueller · Alexander Mueller · Philipp Birnbaumer · Felix Aberer · Gerd Koehler · Caren Sourij · Harald Kojzar · Peter Holler · Helmut Simi · Peter N. Pferschy · Pavel Dietz · Pavel Dietz · Richard M. Bracken · Peter Hofmann · Harald Sourij · Harald Sourij
Role of ghrelin in pancreatic development and function Rebecca K. C. Loh · Melissa Formosa · Andre La Gerche · Anne T. Reutens · Bronwyn A. Kingwell · Andrew L. Carey · Andrew L. Carey
Reduction in insulin degludec dosing for multiple exercise sessions improves time spent in euglycaemia in people with type 1 diabetes: A randomized crossover trial Masanori Shimizu · Kunihiro Suzuki · Kanako Kato · Teruo Jojima · Toshie Iijima · Toshimitsu Murohisa · Makoto Iijima · Hidehiro Takekawa · Isao Usui · Hideyuki Hiraishi · Yoshimasa Aso · Yoshimasa Aso
Islet stress, degradation and autoimmunity Attilio Pingitore · Noemi Gonzalez-Abuin · Inmaculada Ruz-Maldonado · Guo Cai Huang · Gary Frost · Shanta J. Persaud · Shanta J. Persaud
Acute metabolic and cardiovascular effects of mirabegron in healthy individuals Hiddo J. Lambers Heerspink · Dennis L. Andress · George L. Bakris · Ricardo Correa-Rotter · Fan Fan Hou · Dalane W. Kitzman · Donald E. Kohan · Hirofumi Makino · John J.V. McMurray · Vlado Perkovic · Sheldon W. Tobe · Melissa Wigderson · Tingting Yi · Hans-Henrik Parving · Dick de Zeeuw · Dick de Zeeuw
Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis Rafael Simó · Cristina Hernández · Cristina Hernández
Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease Chintan V. Dave · Sebastian Schneeweiss · Elisabetta Patorno · Elisabetta Patorno
Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial Gregory A. Nichols · Sephy Philip · Kristi Reynolds · Craig Granowitz · Sergio Fazio · Sergio Fazio
Comment on:Glucagon-like peptide-1 receptor expression in the human eye Andrea Natali · Lorenzo Nesti · Elena Venturi · Angela C. Shore · Faisel Khan · Km Gooding · Phillip E. Gates · Helen C. Looker · Fiona Dove · Isabel Gonçalves · Margaretha Persson · Jan Nilsson · Jan Nilsson
Comparative risk of genital infections associated with SGLT2 inhibitors: A real‐world retrospective cohort study Stephen C. Bain · Michael A Klufas · Allen C. Ho · David R. Matthews · David R. Matthews
Increased Residual Cardiovascular Risk in Patients with Diabetes and High vs. Normal Triglycerides Despite Statin‐Controlled LDL Cholesterol Gergő Mészáros · Adrien Pasquier · Kevin Vivot · Alexander Goginashvili · Romeo Ricci · Romeo Ricci
Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: A nested, case-control study Jonathan Lou S. Esguerra · Mototsugu Nagao · Jones K. Ofori · A. Wendt · Lena Eliasson · Lena Eliasson
Worsening diabetic retinopathy with rapid improvement in systemic glucose control: a review Sofia Thomaidou · Arnaud Zaldumbide · Bart O. Roep · Bart O. Roep · Bart O. Roep
Lysosomes in nutrient signalling: A focus on pancreatic β-cells Volodymyr Petrenko · Jacques Philippe · Charna Dibner · Charna Dibner
MicroRNAs in islet hormone secretion Jing W. Hughes · Alessandro Ustione · Zeno Lavagnino · David W. Piston · David W. Piston
NHE3 Blockade Ameliorates Type 2 Diabetes Mellitus via Inhibition of SGLT1-Mediated Glucose Absorption in the Small Intestine Liyue Tong · Chunshen Pan · Hongwei Wang · Monica Bertolini · Elisheva Lew · Luigi Meneghini · Luigi Meneghini
Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study Milton Packer · Milton Packer
Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers Gijs W. D. Landman · Nanne Kleefstra · Kornelis J. J. van Hateren · Kornelis J. J. van Hateren
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study Claudiane Guay · Romano Regazzi · Romano Regazzi
Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes Dm Philip Home DPhil · Francoise Calvi-Gries · Lawrence Blonde · Valerie Pilorget · Joseph Berlingieri · Nick Freemantle · Nick Freemantle
Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes Hermione Price MBChB · Matthias Blüher · Rudolf Prager · Tra-Mi Phan · Brian Larsen Thorsted · Bernd Schultes · Bernd Schultes
Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study Linong Ji · Jing Liu · Jing Yang · Yufeng Li · Li Liang · Dalong Zhu · Quanmin Li · Tianrong Ma · Haiyan Xu · Yanlan Yang · Jiaoe Zeng · Bo Feng · Shen Qu · Yiming Li · Lizhen Ma · Shanshan Lin · Jianping Wang · Wei Li · Weihong Song · Xiaoxing Li · Yong Luo · Shugang Xi · Mei Lin · Yu Liu · Zerong Liang · Zerong Liang
Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study Muhammad A. Abdul-Ghani · Muhammad A. Abdul-Ghani · Osama Migahid · Ayman Megahed · Rajvir Singh · Dalia Kamal · Ralph A. DeFronzo · Amin Jayyousi · Amin Jayyousi
Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: Analysis of results from the CONSENT trial Fang Liz Zhou · Fen Ye · Paulos Berhanu · Vineet Gupta · Rishab Gupta · Jennifer Sung · Jukka Westerbacka · Timothy S. Bailey · Lawrence Blonde · Lawrence Blonde
Insulin secretion predicts the response to therapy with exenatide plus pioglitazone, but not to basal/bolus insulin in poorly controlled T2DM patients: Results from the Qatar study Richard E. Pratley · Roy Eldor · Annaswamy Raji · Gregory T. Golm · Susan Huyck · Yanping Qiu · Sheila Sunga · Jeremy Johnson · Steven G. Terra · James P. Mancuso · Samuel S. Engel · Brett Lauring · Brett Lauring
Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin Julio Rosenstock · Juan P. Frías · Dénes Páll · Bernard Charbonnel · Raluca Pascu · Didier Saur · Amanda Darekar · Susan Huyck · Harry Shi · Brett Lauring · Steven G. Terra · Steven G. Terra
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial Bernard Thorens · Domenico Accili · Bo Ahrén · Christian Boitard · Susumu Seino · Erol Cerasi · Erol Cerasi
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET) Eric Zijlstra · Hans-Veit Coester · Tim Heise · Leona Plum-Mörschel · Ole Rasmussen · Tord Rikte · Line Kynemund Pedersen · Marianne Qvist · Thomas Sparre · Thomas Sparre
Injecting without pressing a button: An exploratory study of a shield-triggered injection mechanism Stuart S. Wightman · Christopher A. R. Sainsbury · Gregory C. Jones · Gregory C. Jones
The effect of low-volume high-intensity interval training versus endurance training on glycemic control in individuals with type 2 diabetes Jeremy Pettus · Dominic N. Reeds · Tricia Santos Cavaiola · Schafer Boeder · Michelle Levin · Garry S. Tobin · Edda Cava · Dung Thai · Jim Shi · Hai Yan · Edgar Bautista · John McMillan · Roger H. Unger · Robert R. Henry · Samuel Klein · Samuel Klein
Visit-to-visit HbA1c variability and systolic blood pressure (SBP) variability are significantly and additively associated with mortality in individuals with type 1 diabetes: An observational study Anisoara Bumbu · Abdul Moutairou · Abdul Moutairou · Odette Matar · Frédéric Fumeron · Frédéric Fumeron · Gilberto Velho · Gilberto Velho · J.-P. Riveline · J.-P. Riveline · Jean-François Gautier · Jean-François Gautier · Michel Marre · Michel Marre · Ronan Roussel · Ronan Roussel · Louis Potier · Louis Potier · Louis Potier
Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial Fang Liz Zhou · L. Xie · Chunshen Pan · Y. Wang · Neel Vaidya · Fen Ye · Ronald Preblick · Luigi Meneghini · Luigi Meneghini
Non-severe hypoglycaemia is associated with weight gain in patients with type 1 diabetes: Results from the Diabetes Control and Complication Trial Suk Chon · Sang Youl Rhee · Kyu Jeung Ahn · Sei Hyun Baik · Yongsoo Park · Moon Suk Nam · Kwan Woo Lee · Soon Jib Yoo · Gwanpyo Koh · Dae Ho Lee · Young Seol Kim · Jeong-Taek Woo · Kiit study investigators · Kiit study investigators
Relationship between treatment persistence and A1C trends among patients with type 2 diabetes newly initiating basal insulin Maaike C. Gerards · Gerdien E. Venema · Kornelis W. Patberg · Martijn Kross · Bert Jan Potter van Loon · Ilse M. G. Hageman · Dominic Snijders · Dees P. M. Brandjes · Joost B. L. Hoekstra · Titia M. Vriesendorp · Victor E. A. Gerdes · Victor E. A. Gerdes
Long-term effects on glycaemic control and β-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial Elizabeth G. Mietlicki-Baase · Claudia G. Liberini · Jayme L. Workinger · Ron L. Bonaccorso · Tito Borner · David J. Reiner · Kieran Koch-Laskowski · Lauren E. McGrath · Rinzin Lhamo · Lauren M. Stein · Bart C. De Jonghe · George G. Holz · Christian L. Roth · Robert P. Doyle · Robert P. Doyle · Matthew R. Hayes · Matthew R. Hayes
Dapagliflozin for prednisone-induced hyperglycemia in acute exacerbation of chronic obstructive pulmonary disease Milton Packer · Milton Packer
A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents Itamar Raz · Marc P. Bonaca · Avivit Cahn · Eri Toda Kato · Michael G. Silverman · Deepak L. Bhatt · Lawrence A. Leiter · Darren K. McGuire · John Wilding · Ingrid Gause-Nilsson · Anna Maria Langkilde · Peter A. Johansson · Marc S. Sabatine · Stephen D. Wiviott · Stephen D. Wiviott
Morbid obesity and type 2 diabetes alter intestinal fatty acid uptake and blood flow Olga Montvida · Olga Montvida · Jonathan E. Shaw · Lawrence Blonde · Sanjoy K. Paul · Sanjoy K. Paul · Sanjoy K. Paul
DECLARE-TIMI 58: Participants baseline characteristics Niels Porksen · Helle Linnebjerg · Eric Chen Quin Lam · Parag Garhyan · Alok Pachori · Richard E. Pratley · Steven R. Smith · Steven R. Smith
Effect of prandial treatment timing adjustment, based on continuous glucose monitoring, in patients with type 2 diabetes uncontrolled with once-daily basal insulin: A randomized, phase IV study Luigi Meneghini · Lulu K. Lee · Shaloo Gupta · Ron Preblick · Ron Preblick
Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus Elke Dorenbos · Elke Dorenbos · Mathijs Drummen · Jesse Rijks · Tanja C. Adam · Pauline Stouthart · J. Alfredo Martínez · J. Alfredo Martínez · Santiago Navas-Carretero · Santiago Navas-Carretero · Gareth Stratton · Nils Swindell · Mikael Fogelholm · Anne Raben · Margriet S. Westerterp-Plantenga · Anita Vreugdenhil · Anita Vreugdenhil · Anita Vreugdenhil
Association of hypoglycaemia severity with clinical, patient-reported and economic outcomes in US patients with type 2 diabetes using basal insulin Serge Jabbour · Juan P. Frías · Cristian Guja · Elise Hardy · Azazuddin Ahmed · Peter Öhman · Peter Öhman
Initiation of dapagliflozin and treatment-emergent fractures Milton Packer · Milton Packer
Comparison of glucose‐lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta‐analysis of randomized controlled trials Petra El Khoury · Petra El Khoury · Ronan Roussel · Ronan Roussel · Frédéric Fumeron · Frédéric Fumeron · Yara Abou-Khalil · Yara Abou-Khalil · Gilberto Velho · Kamel Mohammedi · Marie-Paule Jacob · Marie-Paule Jacob · Philippe Gabriel Steg · Louis Potier · Louis Potier · Youmna Ghaleb · Youmna Ghaleb · Youmna Ghaleb · Sandy Elbitar · Sandy Elbitar · Sandy Elbitar · Stéphanie Ragot · Stéphanie Ragot · Francesco Andreata · Francesco Andreata · Giusepinna Caligiuri · Giusepinna Caligiuri · Samy Hadjadj · Catherine Boileau · Catherine Boileau · Michel Marre · Michel Marre · Marianne Abifadel · Marianne Abifadel · Mathilde Varret · Mathilde Varret · Boris Hansel · Boris Hansel · Boris Hansel
Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects Konstantinos A. Toulis · John P. Bilezikian · G. Neil Thomas · Wasim Hanif · Kalliopi Kotsa · Rasiah Thayakaran · Deepiksana Keerthy · Abd A. Tahrani · Krishnarajah Nirantharakumar · Krishnarajah Nirantharakumar
Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: results from the SUPER study, a randomized, double-blind, placebo-controlled trial Judith van Dalem · Judith van Dalem · Martijn C. G. J. Brouwers · Coen D. A. Stehouwer · André Krings · Olaf H. Klungel · Johanna H. M. Driessen · Frank de Vries · Frank de Vries · Frank de Vries · Andrea M. Burden · Andrea M. Burden · Andrea M. Burden · Andrea M. Burden
Metformin for the Management of Peri-operative Hyperglycemia Nobuya Inagaki · Shin-ichi Harashima · Kohei Kaku · Kazuoki Kondo · Nobuko Maruyama · Makiko Otsuka · Yutaka Kawaguchi · Hiroaki Iijima · Hiroaki Iijima
Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: a longitudinal study of a US administrative claims database Craig John Currie · Sarah E. Holden · Sara Jenkins-Jones · Christopher Ll. Morgan · Bernd Voss · Swapnil Rajpathak · Berhanu Alemayehu · J. R. Peters · Samuel S. Engel · Samuel S. Engel
Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus Thorsten Siegmund · Nikolaos Tentolouris · Søren T. Knudsen · Annunziata Lapolla · Rudolf Prager · Tra-Mi Phan · Michael Lyng Wolden · Bernd Schultes · Bernd Schultes
Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival Moe Thuzar · Moe Thuzar · W. Phillip Law · W. Phillip Law · Jeyakantha Ratnasingam · Christina Jang · Christina Jang · Goce Dimeski · Goce Dimeski · Ken Ky Ho · Ken Ky Ho · Ken Ky Ho
A European, multicentre, retrospective, non-interventional study (EU-TREAT) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes Tony Jourdan · Joshua K. Park · Zoltán V. Varga · János Pálóczi · Nathan J. Coffey · Avi Z. Rosenberg · Avi Z. Rosenberg · Grzegorz Godlewski · Resat Cinar · Ken Mackie · Pál Pacher · George Kunos · George Kunos
Glucocorticoids suppress brown adipose tissue function in humans: a double-blind placebo-controlled study Edward S. Chambers · Claire S. Byrne · Karen Aspey · Yanjie Chen · Saadiyah Khan · Douglas J. Morrison · Gary Frost · Gary Frost
Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy Motoshi Ouchi · Kenzo Oba · Kohei Kaku · Hideki Suganami · Akihiro Yoshida · Yasunori Fukunaka · Promsuk Jutabha · Asuka Morita · Naoyuki Otani · Keitaro Hayashi · Tomoe Fujita · Tatsuya Suzuki · Masahiro Yasutake · Naohiko Anzai · Naohiko Anzai
Acute oral sodium propionate supplementation raises resting energy expenditure and lipid oxidation in fasted humans Jeannie Tay · Jeannie Tay · Jeannie Tay · Campbell H. Thompson · Natalie D. Luscombe-Marsh · Thomas P. Wycherley · Manny Noakes · Jonathan D. Buckley · Gary A. Wittert · William S. Yancy · William S. Yancy · Grant D. Brinkworth · Grant D. Brinkworth
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin Yingli Chen · Xiaomin Liu · Quanmin Li · Jianhua Ma · Xiaofeng Lv · Lixin Guo · Changjiang Wang · Yongquan Shi · Yanbing Li · Eva Johnsson · Mei Wang · June Zhao · Linong Ji · Linong Ji
Effects of an energy-restricted low-carbohydrate, high unsaturated fat/low saturated fat diet versus a high-carbohydrate, low-fat diet in type 2 diabetes: a 2-year randomized clinical trial Shani Botha · Lorna Forde · Sheila MacNaughton · Ross Shearer · Robert S. Lindsay · Naveed Sattar · David Morrison · Paul Welsh · Jennifer Logue · Jennifer Logue
Effect of non‐surgical weight management on weight and glycaemic control in people with type 2 diabetes: a comparison of interventional and non‐interventional outcomes at 3 years Pegah Poursharifi · Sri Ramachandra Murthy Madiraju · Marc Prentki · Marc Prentki
Overtreatment of older patients with type 2 diabetes mellitus in primary care Francesco Zaccardi · Nafeesa N. Dhalwani · Jolyon Dales · Hamid Mani · Kamlesh Khunti · Melanie J. Davies · David R. Webb · David R. Webb
Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study Stefano Del Prato · Robert Chilton · Robert Chilton
Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors Anita M. Loughlin · Qing Qiao · Anthony P. Nunes · Peter Öhman · Stephen M. Ezzy · Laura Yochum · C. Robin Clifford · Robert Gately · David D. Dore · John D. Seeger · John D. Seeger
Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials Dan Siskind · Dan Siskind · Anthony W. Russell · Anthony W. Russell · Clare Gamble · Karl Winckel · Karl Winckel · Karla Mayfield · Sam Hollingworth · Ingrid J. Hickman · Victor Siskind · Steve Kisely · Steve Kisely
Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States Inmaculada Ruz-Maldonado · Attilio Pingitore · Bo Liu · Patricio Atanes · Guo Cai Huang · David Baker · Francisco J. Alonso · Francisco Javier Bermúdez-Silva · Shanta J. Persaud · Shanta J. Persaud
Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX) Jarna C. Hannukainen · Riikka Lautamäki · Jussi P. Pärkkä · Marjatta Strandberg · Virva Saunavaara · Saija Hurme · Minna Soinio · Prince Dadson · Kirsi A. Virtanen · Tove Grönroos · Tove Grönroos · Sarita Forsback · Paulina Salminen · Pirjo Nuutila · Pirjo Nuutila · Pirjo Nuutila
LH-21 and abnormal cannabidiol improve β-cell function in isolated human and mouse islets through GPR55-dependent and -independent signalling Elisabetta Patorno · Chandrasekar Gopalakrishnan · Jessica M. Franklin · Kimberly G. Brodovicz · Elvira Masso-Gonzalez · Dorothee B. Bartels · Dorothee B. Bartels · Jun Liu · Sebastian Schneeweiss · Sebastian Schneeweiss
Reversibility of myocardial metabolism and remodelling in morbidly obese patients 6 months after bariatric surgery Lene Jensen · Viera Kupčová · Gerhard Arold · Jonas Pettersson · Julie Hjerpsted · Julie Hjerpsted
Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records Kristie Aamodt · Alvin C. Powers · Alvin C. Powers · Alvin C. Powers
Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment Dana Avrahami · Yue J. Wang · Agnes Klochendler · Yuval Dor · Benjamin Glaser · Klaus H. Kaestner · Klaus H. Kaestner
Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes Huberta E. Hart · Guy E.H.M. Rutten · Kyra N. Bontje · Rimke C. Vos · Rimke C. Vos
PREVIEW (Prevention of Diabetes Through Lifestyle Intervention and Population Studies in Europe and Around the World) study in children aged 10 to 17 years: Design, methods and baseline results Mette V. Jensen · Jessica R. Gooding · Mourad Ferdaoussi · Xiao-Qing Dai · Brett S. Peterson · Patrick E. MacDonald · Christopher B. Newgard · Christopher B. Newgard
Have we really demonstrated the cardiovascular safety of anti-hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes Jacob Ilany · Hamad Bhandari · Dan Nabriski · Yoel Toledano · Noa Konvalina · Ohad Cohen · Ohad Cohen
Metformin does not affect postabsorptive hepatic free fatty acid uptake, oxidation or resecretion in humans: A 3-month placebo-controlled clinical trial in patients with type 2 diabetes and healthy controls Stefano Del Prato · Julio Rosenstock · Ricardo Garcia-Sanchez · Nayyar Iqbal · Lars Hansen · Eva Johnsson · Hungta Chen · Chantal Mathieu · Chantal Mathieu
Epigenetic effects of metformin: From molecular mechanisms to clinical implications Adrian Heald · Adrian Heald · Anthony A. Fryer · Simon G. Anderson · Mark Livingston · Mark Lunt · Mark Davies · Gabriela Y. C. Moreno · Roger Gadsby · R. Young · Mike Stedman · Mike Stedman
Sodium–glucose co‐transporter 2 inhibitors (SGLT2Is) – The latest residents on the block: Impact on glycaemic control at a general practice level in England Ananda Basu · Thomas R. Pieber · Ann Kathrine Hansen · Stefanie Sach-Friedl · Lars Erichsen · Rita Basu · Hanne Haahr · Hanne Haahr
Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin Ronnie Aronson · Juan P. Frías · Allison Goldman · Amanda Darekar · Brett Lauring · Steven G. Terra · Steven G. Terra
Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis Lars Christian Gormsen · Esben Søndergaard · Nana Louise Christensen · Steen Jakobsen · Erik H. T. Nielsen · Ole Lajord Munk · Lars Poulsen Tolbod · Niels Jessen · Niels Jessen · Søren Nielsen · Søren Nielsen
Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart Leo F. Buckley · Dave L. Dixon · George F. Wohlford · Dayanjan S. Wijesinghe · William L. Baker · Benjamin W. Van Tassell · Benjamin W. Van Tassell
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study Sara Charleer · Sara Charleer · Chantal Mathieu · Frank Nobels · Pieter Gillard · Pieter Gillard
Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer Konstantinos Kantartzis · Louise Fritsche · Maria Bombrich · Jürgen Machann · Fritz Schick · Harald Staiger · Iris Kunz · Rotraut Schoop · Angela Lehn-Stefan · Martin Heni · Andreas Peter · Andreas Fritsche · Hans-Ulrich Häring · Norbert Stefan · Norbert Stefan
Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: A 1-year randomized study Ravi Retnakaran · Ravi Retnakaran · Ravi Retnakaran · Haysook Choi · Chang Ye · Caroline K. Kramer · Caroline K. Kramer · Bernard Zinman · Bernard Zinman · Bernard Zinman · Bernard Zinman
Specific synbiotics in early life protect against diet-induced obesity in adult mice Milton Packer · Milton Packer
Effect of intensive blood pressure control in patients with type 2 diabetes mellitus over 9 years of follow-up: A subgroup analysis of high-risk ACCORDION trial participants Paresh Dandona · Husam Ghanim · Ajay Chaudhuri · Ajay Chaudhuri
SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis Andreas Brønden · Kristian Hallundbæk Mikkelsen · David P. Sonne · Morten Hartvig Hansen · Christoffer Våben · Maria Buur Nordskov Gabe · Mette M. Rosenkilde · Valentina Tremaroli · Hao Wu · Fredrik Bäckhed · Fredrik Bäckhed · Jens F. Rehfeld · Jens J. Holst · Tina Vilsbøll · Filip K. Knop · Filip K. Knop
Accuracy and precision of flash glucose monitoring sensors inserted into the abdomen and upper thigh compared with the upper arm Gian Paolo Fadini · Giancarlo Zatti · Ileana Baldi · Daniele Bottigliengo · Agostino Consoli · Andrea Giaccari · Giorgio Sesti · Angelo Avogaro · Angelo Avogaro
Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin Luke J. Laffin · George L. Bakris · George L. Bakris
Incretins: Beyond type 2 diabetes Ying Li · Ying Li · Tao Zhang · Tao Zhang · Tianshu Han · Shengxu Li · Lydia A. Bazzano · Jiang He · Wei Chen · Wei Chen
Use and effectiveness of dapagliflozin in routine clinical practice. An Italian multicenter retrospective study Suzanne V. Arnold · Mikhail Kosiborod · Jingyan Wang · Peter Fenici · Goran Gannedahl · Robert J. LoCasale · Robert J. LoCasale
Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes Tomohide Yamada · Ryuichi Kamata · Kotomi Ishinohachi · Nobuhiro Shojima · Sophia Ananiadou · Hisashi Nom · Toshimasa Yamauchi · Takashi Kadowaki · Takashi Kadowaki
Impact of cigarette smoking on the relationship between body mass index and insulin: Longitudinal observation from the Bogalusa Heart Study Vanita R. Aroda · Vanita R. Aroda
Burden of cardio-renal-metabolic conditions in adults with type 2 diabetes within the Diabetes Collaborative Registry Dandan Li · Weilong Shi · Tiansheng Wang · Huilin Tang · Huilin Tang · Huilin Tang
Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus Marie-Ève Piché · Anne-Sophie Laberge · Patrice Brassard · Benoit J. Arsenault · Olivier F. Bertrand · Jean-Pierre Després · Olivier Costerousse · Paul Poirier · Paul Poirier
Biosimilar vs originator insulins: Systematic review and meta-analysis Fernando Bril · Fernando Bril · Laura Millán · Srilaxmi Kalavalapalli · Michael J. McPhaul · Michael P. Caulfield · Ibon Martínez-Arranz · Cristina Alonso · Pablo Ortiz Betes · José M. Mato · Kenneth Cusi · Kenneth Cusi · Kenneth Cusi
SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis Mona Mischke · Tulika Arora · Sebastian Tims · Eefje Engels · Nina Sommer · Kees van Limpt · Annemarie Baars · Raish Oozeer · Annemarie Oosting · Fredrik Bäckhed · Fredrik Bäckhed · Jan Knol · Jan Knol
Comment on:Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, −4 and −5 trials Ye-Xuan Cao · Hui-Hui Liu · Qiu-Ting Dong · Sha Li · Jian-Jun Li · Jian-Jun Li
Comparisons of diabetic retinopathy events associated with glucose‐lowering drugs in patients with type 2 diabetes mellitus: A network meta‐analysis Angus G. Jones · Angus G. Jones · Timothy J. McDonald · Timothy J. McDonald · Timothy J. McDonald
Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis Ellen M. Apperloo · Michelle J. Pena · Dick de Zeeuw · Petra Denig · Hiddo J. Lambers Heerspink · Hiddo J. Lambers Heerspink
Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post‐hoc analysis of the AWARD‐2, ‐4 and ‐5 Trials Carolyn F. Deacon · Carolyn F. Deacon
Tofogliflozin decreases body fat mass and improves peripheral insulin resistance Matteo Monami · Francesco Liistro · Alessia Scatena · Besmir Nreu · Edoardo Mannucci · Edoardo Mannucci
Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS) Paul Denver · Victor Gault · Paula L. McClean · Paula L. McClean
Short and medium‐term efficacy of sodium glucose co‐transporter‐2 (SGLT‐2) inhibitors: A meta‐analysis of randomized clinical trials Chantal Mathieu · Bruce W. Bode · Edward Franek · Athena Philis-Tsimikas · Ludger Rose · Tina Graungaard · Anne Birk Østerskov · David Russell-Jones · David Russell-Jones
Sustained high-fat diet modulates inflammation, insulinsignalling and cognition in mice and a modified xenin peptideameliorates neuropathology in a chronic high-fat model Kohei Kaku · Yuichiro Yamada · Hirotaka Watada · Atsuko Abiko · Tomoyuki Nishida · Jeppe Zacho · Arihiro Kiyosue · Arihiro Kiyosue
Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial Nitin Gholap · Felix A. Achana · Melanie J. Davies · Kausik K. Ray · Laura J. Gray · Kamlesh Khunti · Kamlesh Khunti
Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial Tina Vilsbøll · Stephen C. Bain · Lawrence A. Leiter · Ildiko Lingvay · David R. Matthews · Rafael Simó · Ida Carøe Helmark · Nelun Wijayasinghe · Michael Larsen · Michael Larsen
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy Naresh Aggarwal · Anuj Singla · Chantal Mathieu · Eduard Montanya · Andreas F.H. Pfeiffer · Eva Johnsson · June Zhao · Nayyar Iqbal · Clifford J. Bailey · Clifford J. Bailey
Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study Claire C J Dekkers · Sergei Petrykiv · Gozewijn D. Laverman · David Z.I. Cherney · David Z.I. Cherney · Ron T. Gansevoort · Hiddo J. Lambers Heerspink · Hiddo J. Lambers Heerspink
Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes Kausik K. Ray · Lawrence A. Leiter · Dirk Müller-Wieland · Bertrand Cariou · Helen M. Colhoun · Robert R. Henry · Francisco J. Tinahones · Maja Bujas-Bobanovic · Catherine Domenger · Alexia Letierce · Rita Samuel · Stefano Del Prato · Stefano Del Prato
Performance of individually measured vs population-based C-peptide kinetics to assess β-cell function in the presence and absence of acute insulin resistance Maria Pompea Antonia Baldassarre · Andreas Andersen · Agostino Consoli · Filip K. Knop · Tina Vilsbøll · Tina Vilsbøll
Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial Laura McCreight · Tore Bjerregaard Stage · Paul Connelly · Mike Lonergan · Flemming Nielsen · Cornelia Prehn · Jerzy Adamski · Kim Brøsen · Ewan R. Pearson · Ewan R. Pearson
Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial Jukka Koffert · Jukka Koffert · Mia Ståhle · Henry K. Karlsson · Paulina Salminen · Anne Roivainen · Pirjo Nuutila · Pirjo Nuutila · Pirjo Nuutila
Cardiovascular biomarkers in clinical studies of type 2 diabetes Timothy M. E. Davis · Hillary Mulder · Yuliya Lokhnygina · Pablo Aschner · Lee-Ming Chuang · Carlos Raffo Grado · Eberhard Standl · Eric D. Peterson · R R Holman · R R Holman
Two-year trial of intermittent insulin therapy vs metformin for the preservation of β-cell function after initial short-term intensive insulin induction in early type 2 diabetes Paolo Pozzilli · Richard David Leslie · Anne L. Peters · Raffaella Buzzetti · Sudha S. Shankar · Zvonko Milicevic · Imre Pavo · Jeremie Lebrec · Sherry Martin · Nanette C. Schloot · Nanette C. Schloot
Pharmacokinetics of metformin in patients with gastrointestinal intolerance Elizabeth R. Seaquist · Hélène Dulude · Xiaotian M. Zhang · Rémi Rabasa-Lhoret · George Tsoukas · James R. Conway · S. J. Weisnagel · Gregg Gerety · Vincent Woo · Shuyu Zhang · Dolorès Carballo · Sheetal Pradhan · Claude A. Piché · Cristina B. Guzman · Cristina B. Guzman
Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Huilin Tang · Huilin Tang · Guangyao Li · Ying Zhao · Fei Wang · Emily W. Gower · Luwen Shi · Tiansheng Wang · Tiansheng Wang · Tiansheng Wang
Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real‐world setting Stephanie Claire Bridgeman · Gaewyn Ellison · Phillip E. Melton · Phillip E. Melton · Philip Newsholme · Cyril Mamotte · Cyril Mamotte
A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials Man Guo · Jingya Ding · Jingsong Li · Jiying Wang · Ting Zhang · Cuiping Liu · Wei Huang · Yang Long · Chenlin Gao · Yong Xu · Yong Xu
Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes Jinya Huang · Yehong Yang · Renming Hu · Lili Chen · Lili Chen
β-Cell signalling and insulin secretagogues: A path for improved diabetes therapy Robert Ritzel · Ronan Roussel · Ronan Roussel · Ronan Roussel · Andrea Giaccari · Jiten Vora · Claire Brulle-Wohlhueter · Hannele Yki-Järvinen · Hannele Yki-Järvinen
NMDAR antagonists for the treatment of diabetes mellitus-Current status and future directions: WELTERS et al Thomas Nyström · Martin J. Holzmann · Martin J. Holzmann · Björn Eliasson · Ann-Marie Svensson · Ann-Marie Svensson
Recent new insights into the role of SNARE and associated proteins in insulin granule exocytosis Ye Seul Yang · Min Hyuk Lim · Seong Ok Lee · Eun Joo Roh · Chang Ho Ahn · Soo Heon Kwak · Young Min Cho · Sungwan Kim · Andrea Mari · Kyong Soo Park · Hye Seung Jung · Hye Seung Jung
Metabolomics applied to islet nutrient sensing mechanisms Andreas Müller · Hassan Mziaut · Martin Neukam · Klaus-Peter Knoch · Michele Solimena · Michele Solimena
Monoacylglycerol signalling and ABHD6 in health and disease Haining Wang · Ye Liu · Qing Tian · Jin Yang · Ran Lu · Siyan Zhan · Jari Haukka · Tianpei Hong · Tianpei Hong
Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences Wiebe Top · Coen D. A. Stehouwer · Philippe Lehert · Adriaan Kooy · Adriaan Kooy
Signals in the pancreatic islet microenvironment influence β-cell proliferation Sudhir Unni · Eric Wittbrodt · Junjie Ma · Marisa Schauerhamer · Jeff Hurd · Natalia Ruiz-Negrón · Carrie McAdam-Marx · Carrie McAdam-Marx · Carrie McAdam-Marx
β-Cells are not uniform after all-Novel insights into molecular heterogeneity of insulin-secreting cells: AVRAHAMI et al Anjaneyulu Kowluru · Anjaneyulu Kowluru
Highlights from the 77th Scientific Sessions of the American Diabetes Association Scientific Meeting, 9-13 June 2017, San Diego, USA Jingtao Dou M.D. · Jianhua Ma · Jun Liu · Changjiang Wang · Eva Johnsson · Hui Yao · June Zhao · Changyu Pan · Changyu Pan
Exosomes as new players in metabolic organ cross-talk Itaru Kojima · Johan Medina · Yuko Nakagawa · Yuko Nakagawa
Role of G-proteins in islet function in health and diabetes Wathik Alsalim · Olga Göransson · Richard D. Carr · Roberto Bizzotto · Andrea Tura · Giovanni Pacini · Andrea Mari · Bo Ahrén · Bo Ahrén
ß-Cells are not uniform after all-Novel insights into molecular heterogeneity of insulin-secreting cells Philip Home · Lam Rlh · Carofano Wl · Gregory T. Golm · Roy Eldor · Michael F. Crutchlow · Marcos Mc · Rosenstock J · P. Hollander · Baptist Gallwitz · Baptist Gallwitz
Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM‐INSULIN randomized trial Bing Pang · Linhua Zhao · Xin-long Li · Jun Song · Qingwei Li · Xing Liao · Shuo Feng · Xiyan Zhao · Yu-jiao Zheng · Xiao-wen Gou · Qing Ni · Xiaolin Tong · Xiaolin Tong
Dapagliflozin Compared to DPP-4 inhibitors is Associated with Lower Risk of Cardiovascular Events and All-cause Mortality in Type 2 Diabetes Patients (CVD-REAL Nordic): a multinational observational study Maria Inês Alvelos · Jonàs Juan-Mateu · Maikel L Colli · Jean Valéry Turatsinze · Decio L. Eizirik · Decio L. Eizirik
Alain Ktorza, PhD in Memoriam Kamilla Winding · Kamilla Winding · Gregers Winding Munch · Ulrik Winning Iepsen · Gerrit van Hall · Bente Klarlund Pedersen · Stefan P. Mortensen · Stefan P. Mortensen
Combining the GPR40 agonist fasiglifam with sitagliptin improves glycemic control in patients with type 2 diabetes with or without metformin: a randomized, 12-week trial Ron T. Varghese · Chiara Dalla Man · Marcello C. Laurenti · Francesca Piccinini · Anu Sharma · Meera Shah · Kent R. Bailey · Robert A. Rizza · Claudio Cobelli · Adrian Vella · Adrian Vella
Role of the glucose-sensing receptor in insulin secretion Yasuo Terauchi · Masahiro Tamura · Masayuki Senda · Ryoji Gunji · Kohei Kaku · Kohei Kaku
A 4D view on insulin secretory granule turnover in the β-cell: MÜLLER et al Ren Matsuba · Ikuro Matsuba · Mototsugu Shimokawa · Yoshio Nagai · Yasushi Tanaka · Yasushi Tanaka
Sodium–glucose cotransporter 2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: a network and cumulative meta‐analysis of randomized controlled trials Eugenio Cersosimo · Eric L. Johnson · Christina Chovanes · Neil Skolnik · Neil Skolnik
Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials Francesco Zaccardi · David R. Webb · Melanie J. Davies · Nafeesa N. Dhalwani · Gemma Housley · Dominic Shaw · James W. Hatton · Kamlesh Khunti · Kamlesh Khunti
Metabolic responses to exogenous ghrelin in obesity and early after Roux-en-Y gastric bypass in humans Huilin Tang · Huilin Tang · Dandan Li · Jingjing Zhang · Yufeng Li · Tiansheng Wang · Suodi Zhai · Yiqing Song · Yiqing Song
Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus Lori Berard · Mireille Bonnemaire · Marie Mical · Steve Edelman · Steve Edelman
Effect of linagliptin on pulse wave velocity in early type 2 diabetes (RELEASE): a randomized, double-blind, controlled 26-week trial Manel Mata-Cases · Manel Mata-Cases · Josep Franch-Nadal · Jordi Real · Mònica Gratacòs · Flora López-Simarro · Kamlesh Khunti · Didac Mauricio · Didac Mauricio
Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD‐9) Ildiko Lingvay · Stewart B. Harris · Elmar Jaeckel · Keval Chandarana · Mattis F. Ranthe · Esteban Jódar · Esteban Jódar
Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials Tetsuro Tsujimoto · Hiroshi Kajio · M.S.H.S. Takehiro Sugiyama M.D. · M.S.H.S. Takehiro Sugiyama M.D.
Breaking up sedentary time with seated upper body activity can regulate metabolic health in obese high-risk adults: A randomized crossover trial Jorn Woerdeman · Daniele Del Rio · Luca Calani · Etto C. Eringa · Yvo M. Smulders · Erik H. Serné · Erik H. Serné
Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: The randomized MARLINA-T2D trial Harpreet S. Bajaj · Chenglin Ye · Esha Jain · Karri Venn · Eden Stein · Ronnie Aronson · Ronnie Aronson
The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin Per-Henrik Groop · Per-Henrik Groop · Mark E. Cooper · Vlado Perkovic · Berthold Hocher · Berthold Hocher · Keizo Kanasaki · Masakazu Haneda · Guntram Schernthaner · Kumar Sharma · Robert Stanton · Robert D. Toto · Jessica Cescutti · Maud Gordat · Thomas Meinicke · Audrey Koitka-Weber · Sandra Thiemann · Maximilian von Eynatten · Maximilian von Eynatten
The effect of continuous exenatide infusion on cardiac function and perioperative glucose control in cardiac surgery patients: a single-blind, randomized, controlled trial Tania Garito · Ronenn Roubenoff · Marcus Hompesch · Linda Morrow · Katherine Gomez · Daniel Rooks · Charles Meyers · Monte S. Buchsbaum · Srikanth Neelakantham · Therese Swan · Lee Anne Filosa · Didier Laurent · Olivier Petricoul · Marjorie Zakaria · Marjorie Zakaria
Comment on: Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among type 2 diabetes patients: A network and cumulative meta-analysis of randomized controlled trials J. Conceição · Jorge Dores · Francisco Araújo · P. Laires · Richard D. Carr · Kimberly G. Brodovicz · Larry Radican · A.M. Nogueira · A.M. Nogueira
Once-weekly administration of a long-acting FGF21 analogue modulates lipids, bone turnover markers, blood pressure, and body weight differently in obese hypertriglyceridemic subjects and in non-human primates Ronan Roussel · Ronan Roussel · Philippe Gabriel Steg · Kamel Mohammedi · Michel Marre · Michel Marre · Louis Potier · Louis Potier · Louis Potier
Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly William Canovatchel · Jennifer Davidson · Norm Rosenthal · Norm Rosenthal
Projected Long-Term Outcomes in Patients With Type 1 Diabetes Treated With Fast-Acting Insulin Aspart Versus Conventional Insulin Aspart in the Uk Setting Jonathan E. Shaw · Baptist Gallwitz · Jenny Han · Elise Hardy · Guntram Schernthaner · Guntram Schernthaner
Ghrelin receptor inverse agonists as a novel therapeutic approach against obesity-related metabolic disease David Russell-Jones · Simon Heller · Sarah Buchs · Anna Sandberg · Wj Valentine · Barnaby Hunt · Barnaby Hunt
Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial Emilie S. Andersen · Carolyn F. Deacon · Jens J. Holst · Jens J. Holst
Sodium‐glucose co‐transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes Kathrin Abegg · Melanie Hutter · Lynda Whiting · Claudio Pietra · Claudio Giuliano · Thomas A. Lutz · Thomas Riediger · Thomas Riediger
Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial Shawn E. McCandless · Jack A. Yanovski · Jennifer L. Miller · Cary Fu · Lynne M. Bird · Parisa Salehi · Christine L. Chan · Diane E. J. Stafford · M. Jennifer Abuzzahab · David H. Viskochil · Sarah E. Barlow · Moris Angulo · Susan E. Myers · Barbara Y. Whitman · Dennis M. Styne · Elizabeth Roof · Elisabeth M. Dykens · Ann O. Scheimann · Jaret Malloy · Dongliang Zhuang · Kristin Taylor · Thomas E. Hughes · Dennis Kim · Merlin G. Butler · Merlin G. Butler
Comment on:Strengths and Limitations of Healthcare Databases in the Evaluation of Hypoglycaemia Joan Khoo · John Hsiang · Ranu Taneja · Ngai-Moh Law · Tiing-Leong Ang · Tiing-Leong Ang
Insulin-associated weight gain in obese type 2 diabetes mellitus patients – what can be done? Benedetta Maria Bonora · Angelo Avogaro · Gian Paolo Fadini · Gian Paolo Fadini
Fasiglifam for glycemic control in patients with type 2 diabetes: a phase 3, placebo-controlled study Adrian Brown · Nicola Guess · Nicola Guess · Anne Dornhorst · Shahrad Taheri · Shahrad Taheri · Gary Frost · Gary Frost
A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus Tamara S. Hannon · Steven E. Kahn · Kristina M. Utzschneider · Thomas A. Buchanan · Kristen J. Nadeau · Philip Zeitler · David A. Ehrmann · Silva Arslanian · Sonia Caprio · Sharon L. Edelstein · Peter J. Savage · Kieren J. Mather · Kieren J. Mather
LAPSInsulin115: A novel ultra-long-acting basal insulin with a unique action profile John Marcinak · Charles Cao · Douglas Lee · Zhan Ye · Zhan Ye
Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users David Raymond Owens · Louis Monnier · Markolf Hanefeld · Markolf Hanefeld
Pancreatic α-cell mass in obesity Nina Wronkowitz · Thorsten Hartmann · Sven W. Görgens · Daniela Dietze-Schroeder · Ira Indrakusuma · In Young Choi · Sung Hee Park · Youngmi Lee · Se Chang Kwon · Yeonjoo Kang · Marcus Hompesch · Jürgen Eckel · Jürgen Eckel
Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise Anthony P. Nunes · Kristy Iglay · Larry Radican · Samuel S. Engel · Jing Yang · Michael Doherty · David D. Dore · David D. Dore
Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes Johanne H. Ellenbroek · Hendrica A. Töns · Maaike Hanegraaf · Ton J. Rabelink · Marten A. Engelse · Françoise Carlotti · Eelco J.P. de Koning · Eelco J.P. de Koning
Relationship Between Diabetes and Ischemic Injury Among Patients with Revascularized ST-Elevation Myocardial Infarction Juri Park · Sung Woo Park · Kun Ho Yoon · Sung Rae Kim · Kyu Jeung Ahn · Jae Hyuk Lee · Ji Oh Mok · Choon Hee Chung · Kyung Ah Han · Gwan Pyo Koh · Jun Goo Kang · Chang Beom Lee · Seong Hwan Kim · Na Young Kwon · Doo Man Kim · Doo Man Kim
Improving glycaemic control in type 2 diabetes: Stimulate insulin secretion or provide beta-cell rest? Takashi Shibuya · Nobutoshi Fushimi · Miyuka Kawai · Yohei Yoshida · Hiroki Hachiya · Shun Ito · Hiromi Kawai · Noritsugu Ohashi · Akihiro Mori · Akihiro Mori
Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial David Preiss · Adem Y. Dawed · Paul Welsh · Alison Heggie · Angus G. Jones · Jacqueline M. Dekker · Robert W. Koivula · T. Hansen · Caitlin Stewart · R R Holman · Paul W. Franks · M. Walker · Ewan R. Pearson · Naveed Sattar · Naveed Sattar
Intraperitoneal Insulin Delivery Provides Superior Glycemic Regulation to Subcutaneous Insulin Delivery in Model Predictive Control-based Fully-automated Artificial Pancreas in Patients with Type 1 Diabetes: A Pilot Study Sebastian Johannes Reinstadler · Thomas Stiermaier · Charlotte Eitel · Bernhard Metzler · Georg Fuernau · Steffen Desch · Holger Thiele · Ingo Eitel · Ingo Eitel
Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice Christian Seerup Frandsen · Thomas Fremming Dejgaard · Thomas Fremming Dejgaard · Henrik Ullits Andersen · Jens J. Holst · Bolette Hartmann · Birger Thorsteinsson · Sten Madsbad · Sten Madsbad
Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes Amparo de la Peña · Corina Loghin · Xuewei Cui · Xin Zhang · Christoph Kapitza · Ronan P. Kelly · Ronan P. Kelly
The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism Thomas Fremming Dejgaard · Nanna B. Johansen · Christian Seerup Frandsen · Ali Asmar · Lise Tarnow · Lise Tarnow · Filip K. Knop · Sten Madsbad · Henrik Ullits Andersen · Henrik Ullits Andersen
Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture : A retrospective population-based cohort study Stéphanie Laugier-Robiolle · Bruno Vergès · Maëlle Le Bras · Elise Gand · B. Bouillet · Pierre-Jean Saulnier · Cédric Le May · Matthieu Pichelin · Richard Marechaud · Jean-Michel Petit · Samy Hadjadj · Bertrand Cariou · Bertrand Cariou
Exenatide Induces an Increase in Vasodilatory and a Decrease in Vasoconstrictive Mediators Julia Möllmann · Florian Kahles · Corinna Lebherz · Ben Arpad Kappel · Christer Baeck · Frank Tacke · Christian Werner · Massimo Federici · Nikolaus Marx · Michael Lehrke · Michael Lehrke
Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials Johanna H. M. Driessen · Johanna H. M. Driessen · Joop P. W. van den Bergh · Hein A.W. van Onzenoort · Hein A.W. van Onzenoort · Ronald M. A. Henry · Hubert G. M. Leufkens · Frank de Vries · Frank de Vries
Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes Ajay Chaudhuri · Husam Ghanim · Antoine Makdissi · Kelly Green · Sanaa Abuaysheh · Manav Batra · Nitesh D. Kuhadiya · Paresh Dandona · Paresh Dandona
Effect of exenatide on postprandial glucose fluxes, lipolysis, and ß-cell function in non-diabetic, morbidly obese patients Lawrence Blonde · Pavan Chava · Terry Dex · Jay Lin · Elena Nikonova · Ronald Goldenberg · Ronald Goldenberg
Robust GLP‐1 secretion by basic L‐amino acids does not require the GPRC6A receptor Kohei Kaku · Shuuji Sumino · Masafumi Katou · Yuya Nishiyama · Yoshinobu Kinugawa · Yoshinobu Kinugawa
Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies Christoffer Clemmensen · Christinna V. Jørgensen · Sanela Smajilovic · Hans Bräuner-Osborne · Hans Bräuner-Osborne
Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): A double-blind, randomized, placebo-controlled clinical trial Home P · Home P

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era
Diabetes, Obesity and Metabolism | 2018
Adie Viljoen · Christina Stentoft Hoxer · Pierre Johansen · Samuel Malkin · Barnaby Hunt · Stephen C. Bain · Stephen C. Bain
Adjusting insulin doses in patients with type 1 diabetes who use insulin pump and continuous glucose monitoring: Variations among countries and physicians
Diabetes, Obesity and Metabolism | 2018
Stefan Korsatko · Lene Jensen · Martina Brunner · Stefanie Sach-Friedl · Maja D. Tarp · Anders Gaarsdal Holst · Simon Heller · Thomas R. Pieber · Thomas R. Pieber
Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany
Diabetes, Obesity and Metabolism | 2018
Michael F. Crutchlow · John Palcza · Kate Mostoller · Chantal Mahon · April M. Barbour · Michael C. Marcos · Yang Xu · Elaine Watkins · Linda Morrow · Marcus Hompesch · Marcus Hompesch
Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1)
Diabetes, Obesity and Metabolism | 2018
Patrick B. Ryan · John B. Buse · Martijn J. Schuemie · Frank J. DeFalco · Zhong Yuan · Paul E. Stang · Jesse A. Berlin · Norman Rosenthal · Norman Rosenthal
Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes
Diabetes, Obesity and Metabolism | 2018
Brian M. Frier · Wolfgang Landgraf · Mei Zhang · Geremia B. Bolli · David Raymond Owens · David Raymond Owens